WO1994002518A1 - Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof - Google Patents
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof Download PDFInfo
- Publication number
- WO1994002518A1 WO1994002518A1 PCT/US1993/006880 US9306880W WO9402518A1 WO 1994002518 A1 WO1994002518 A1 WO 1994002518A1 US 9306880 W US9306880 W US 9306880W WO 9402518 A1 WO9402518 A1 WO 9402518A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- composition
- alkylene
- composition according
- group
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
Definitions
- the present invention relates to cyclodextrin derivatives and to their pharmaceutical application as clathrating agents.
- Cyclodextrins are a group of cyclic
- Cyclodextrins are cyclic molecules containing six or more ⁇ -D-glucopyranose units linked at the 1,4 positions by ⁇ linkages as in amylose.
- the molecule is characterized as having neither a reducing end group nor a non-reducing end group.
- the molecule is represented below by schematic formula (1) where the hydroxyl groups are shown in the 2, 3, and 6-positions of the glucopyranose units.
- Variable n may be a number from 4 to 6, or higher.
- cyclodextrin it is
- cyclodextrins have the ability to form complexes with a variety of organic and inorganic molecules.
- the formation of cyclodextrin inclusion complexes with molecules is referred to as the
- Cyclodextrins are known generally to improve the dissolution rate of drugs.
- the complexes formed are, however, also stable in aqueous solution, so that the improvement in dissolution is accompanied by an increase in the saturation solubility of the drug.
- cyclodextrins have been described by Parmerter et al (U.S. Patent No. 3,453,259), and Gramera et al (U.S. Patent No. 3,459,731). These are obtained by the condensation reaction of cyclodextrins with various epoxides or organic halides.
- cyclodextrins with cationic properties include cyclodextrins with cationic properties (Parmerter (I); U.S. Patent No. 3,453,257), insoluble crosslinked cyclodextrins (Solms; U.S. Patent No. 3,420,788), and cyclodextrins with anionic properties (Parmerter (II); U.S. Patent No. 3,426,011).
- cyclodextrin derivatives with anionic properties carboxylic acids, phosphorus acids, phosphinous acids, phosphonic acids, phosphoric acids, thiophosphonic acids, thiophosphinic acids, and
- solubility Jones; U.S Patent 4,555,504
- This solubilization results in the improved bioavailability for some drugs.
- As a clathrate complex some drugs have shown improved chemical stability in aqueous solution (Harada et al; U.S. Patent No.
- cyclodextrins in the clinical setting is limited to oral and topical dosage forms as the cyclodextrins exhibit nephrotoxicity upon entering the body
- Cyclodextrins and their derivatives are mostly crystalline solids and concentration in the renal tissue is followed by crystal formation causing
- cyclodextrin drug complexes have been limited in their utility to sublingual administration. Efforts have been made to inhibit crystal formation in cyclodextrin drug complexes by
- the present invention provides purified
- cyclodextrin derivatives present both as single derivatives and as mixtures of derivatives. These are obtained by heating a cyclodextrin starting material with a reagent (s) which introduces a specific anionic- type substituent, i.e., a (C 2-6 alkylene)-SO 3 - anionic substituent, onto the cyclodextrin molecule. These have been discovered to possess notably enhanced aqueous solubility and an advantageously low degree of toxicity. The more highly substituted cyclodextrin derivatives have further been found to advantageously cause essentially no membrane disruption. These derivatized cyclodextrins are useful as clathrating agents in parenteral pharmaceutical formulations and other related uses. BRIEF DESCRIPTION OF THE FIGURES
- FIGURE 1 sets out cumulative urinary cyclodextrin excretion in mice for underivatized cyclodextrin, hydroxy propyl-derivatized cyclodextrin, and two sulfoalkyl cyclodextrin derivatives of the present invention
- FIGURES 2 and 3 provide data showing that the more highly substituted alkylsulfonic acids of the present invention cause less membrane disruption, as determined by red blood cell hemolysis studies, as compared to the mono-substituted alkylsulfonic acid derivatives, with the underivatized cyclodextrin causing the most
- FIGURES 4, 5 and 6 show that the association
- FIGURES 7, 8, 9 and 10 similarly show that with phenytoin and testosterone the sulfoalkyl cyclodextrin derivatives of the present invention possess notably greater association constants as compared to the
- FIGURES 11, 12 and 13 show the results of
- derivatives suitable for pharmaceutical use are suitable for use as clathrating agents with drugs to provide clathrate complexes which are useful in parenteral and other pharmaceutical
- the cyclodextrin derivatives of the present invention are functionalized with (C 2-6 alkylene)-SO 3 - groups, and are thus charged species.
- the fact that these compounds have been discovered to possess a very low level of toxicity is surprising in light of the prior art's belief that cyclodextrin derivatives must retain electroneutrality to sustain lack of toxicity (cf. Pitha, "Amorphous Water-Soluble” "Third int'l Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, Feb. 23-27, 1987).
- heterogeneous mixture of the present cyclodextrin derivatives is not a requirement for the observed enhanced solvation to occur.
- a mixture of sulfoalkyl ether derivatives can be used in accordance with the present invention, such a mixture is not required for enhanced solubility.
- the cyclodextrin derivatives of this invention have structures
- n 4 , 5 or 6 ;
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each, independently , O- or a O- (C 2-6 alkylene ) -SO 3 - group, wherein at least one of R 1 and R 2 is independently a O-(C 2-6 alkylene)-SO 3 -group, preferably a O-(CH 2 )- m SO 3 - group, wherein m is .2 to 6, preferably 2 to 4, (e.g. OCH 2 CH 2 CH 2 SO 3 - or OCH 2 CH 2 CH 2 CH 2 SO 3 -); and
- S 1 , S 2 , S 3 , S 4 , S 5 , S 6 , S 7 , S 8 and S 9 are each, independently, a pharmaceutically acceptable cation which includes, for example, H + , alkali metals (e.g. Li + , Na + , K + ), alkaline earth metals (e.g., Ca +2 , Mg +2 ), ammonium ions and amines cations such as the cations C 1-6 alkylamines, piperidine, pyrazine, C 1-6 alkanolamine and C 4-8 cycloalkanolamine.
- alkali metals e.g. Li + , Na + , K +
- alkaline earth metals e.g., Ca +2 , Mg +2
- ammonium ions and amines cations such as the cations C 1-6 alkylamines, piperidine, pyrazine, C 1-6 alkanolamine and C 4
- R 1 is a O-(C 2-6 alkylene)-SO 3 - group, preferably a O-(CH 2 )- m SO 3 - group, (e.g. OCH 2 CH 2 CH 2 SO 3 - or
- R 2 to R 9 are O-;
- S 1 to S 9 are as defined in embodiment (1) supra.
- R 1 , R 2 and R 3 are each, independently, a O-(C 2-6 - alkylene)-SO 3 - group, preferably a O-(CH 2 ) m SO 3 - group, (e.g. OCH 2 CH 2 CH 2 SO 3 - or OCH 2 CH 2 CH 2 CH 2 SO 3 -);
- R 4 to R 9 are O-;
- S 1 to S 9 are as defined in embodiment (1) supra
- R 1 to R 3 are as defined in embodiments (2) or (3); supra;
- R 4 , R 6 and R 8 is a O-C 2-6 -alkylene)-SO 3 - group, preferably a O-(CH 2 ) m -SO 3 - group (e.g. OCH 2 CH 2 CH 2 SO 3 - or OCH 2 CH 2 CH 2 CH 2 SO 3 -).
- R 5 , R 7 and R 9 are O-;
- S 1 to S 9 are as defined in embodiment (1) supra.
- R 1 , R 2 , R 3 , R 4 , R 6 and R 8 are each, independently, a O-(C 2-6 -alkylene)-SO 3 - group, preferably a
- O-(CH 2 )- m SO 3 - group eg. OCH 2 CH 2 CH 2 SO 3 - or
- R 5 , R 7 and R 9 are O-;
- S 1 to S 9 are as defined in embodiment (1) supra.
- alkylene and alkyl in this text (e.g., in the O-(C 2-6 -alkylene)SO 3 - group or in the alkylamines) include both linear and branched,
- alkanol in this text likewise includes both linear and branched, saturated and unsaturated alkyl components of the alkanol groups, in which the hydroxyl groups may be situated at any position on the alkyl moiety.
- cycloalkanol includes unsubstituted or substituted (e.g., by methyl or ethyl) cyclic alcohols.
- composition overall contains on the average at least 1 and up to 3n + 6 alkylsulfonic acid moieties per cyclodextrin molecule.
- present invention also provides compositions containing essentially only one single type of cyclodextrin derivative.
- the present cyclodextrin derivatives are either substituted at least at one of the primary hydroxyl group (i.e., at least one of R 1 to R 3 is a
- the cyclodextrin derivatives of the present invention are obtained (as discussed below) as purified compositions, preferably as compositions containing at least 95 wt. % of cyclodextrin derivative (s) with the substitution occuring at least on the primary hydroxyl group of the cyclodextrin molecule (i.e. R 1 , R 2 or R 3 of formula (2)), as determined by 300 MHz 1 H NMR).
- purified compositions preferably as compositions containing at least 95 wt. % of cyclodextrin derivative (s) with the substitution occuring at least on the primary hydroxyl group of the cyclodextrin molecule (i.e. R 1 , R 2 or R 3 of formula (2)), as determined by 300 MHz 1 H NMR).
- purified compositions preferably as compositions containing at least 95 wt. % of cyclodextrin derivative (s) with the substitution occuring at least on the primary hydroxyl group of the cyclodextr
- unreacted cyclodextrin has been substantially removed, with the remaining impurities (i.e., ⁇ 5 wt.% of composition) being inconsequential to the performance of the cyclodextrin derivative-containing composition.
- the more highly substituted alkyl sulfonic acid cyclodextrin derivatives of the present invention have been discovered to possess, in addition to notably enhanced solubility characteristics and low toxicity, the advantageous property of causing less membrane disruption.
- the more highly substituted cyclodextrin derivatives demonstrated negligible membrane disruption.
- the mono-substituted cyclodextrin derivatives caused about the same amount of membrane disruption as the hydroxy propyl derivative.
- compositions of the invention which contain ⁇ 5%, preferably less than 2%, of unreacted ⁇ -cyclodextrin, and are particularly important for compositions to be administered to a patient by
- nephrotoxicity An IV administered dose gains access to the kidneys via the route of blood circulation. Once ⁇ -cyclodextrin is filtered by the kidney cells it appears to cause nephrotoxicity due to disruption of cellular membranes caused by removal of cholesterol from the cell membranes. Consequently, there is little tolerance for a derivatized cyclodextrin containing residual ⁇ -cyclodextrin if that product is to be used in a parenteral formulation.
- ⁇ -cyclodextrin In contrast, the allowance for residual ⁇ -cyclodextrin would be broader for a sulfoalkylether cyclodextrin preparation used in an oral formulation.
- the oral absorption of ⁇ -cyclodextrin is limited (if it occurs at all) and the elimination of ⁇ -cyclodextrin in the feces would preclude any nephrotoxicity.
- the level of ⁇ -cyclodextrin which might be tolerated in an oral formulation would still be dependent upon other characteristics of the material particularly on its intrinsic aqueous solubility.
- the sulfoalkylether derivatives of the present invention may be used for oral
- the cyclodextrin derivatives described may be generally prepared by dissolving the cyclodextrin in aqueous base at an appropriate temperature, e.g., 70° to 80°C, at the highest concentration possible.
- an appropriate temperature e.g. 70° to 80°C
- cyclodextrin derivatives of the embodiment (2) a molar amount of the alkyl sultone, corresponding to the number of moles of CD used, is used.
- an amount of alkyl sultone between that stated above is used.
- Other cyclodextrin derivatives provided by the present invention are prepared Mutatis Mutandis.
- the mixtures are allowed to react until one phase results which is indicative of depletion of the alkyl sultone.
- the reaction mixture is diluted with an equal volume of water and neutralized with an acid such as hydrochloric acid.
- the solution is then dialyzed to remove impurities followed by concentration of the solution by ultrafiltration.
- the concentrated solution is then subjected to ion-exchange chromatography to remove unreacted cyclodextrin, and then freeze-dried to yield the desired product.
- the CD used in this invention may be any CD obtained by known methods, e.g., by the action of cyclodextrin-glucanotransferase (CGTase, E.C.,
- CD herein means ⁇ -CD in which six glucose units are linked together
- ⁇ -CD in which seven glucose units are linked together
- ⁇ -CD in which eight glucose units are linked together, or a mixture thereof.
- use of ⁇ -CD is most preferred for production of partially derivatized products of broad utility.
- the amount of alkyl sultone used as the derivatizing agent should be not more than about one molar equivalent, based on the number of primary hydroxyl groups present in the CD, although the optimum amount may be somewhat dependent on the reactant concentration.
- Lithium hydroxide, sodium hydroxide and potassium hydroxide may be used as the accelerator. Of these, sodium hydroxide is preferable because of the its low cost. Its amount must be more than about 30 molar equivalents, and should preferably be in the range of 80 to 200 molar equivalents, with the reactant concentration being set at a level higher than 10% (wt/wt), preferably in the range of 40 to 60% (wt/wt).
- reaction medium Any solvent which is substantially inert to the partial alkylation may be used as reaction medium.
- Typical examples are water, DMF, DMSO, and mixtures thereof, but use of water alone is most preferred for ease of after-treatment.
- the type and concentration of alkylsultone and alkali are not critical to the reaction. However, the reaction is normally carried out with stirring at 10 to 80°C for one hour, preferably at 20° to 50°C for 5 to 20 hours.
- Techniques commonly used in this field may be employed to isolate and purify the objective compounds from reaction mixtures. These include extraction with organic solvents, dialysis, adsorption chromatography with activated charcoal, silica gel, alumina and other adsorbents, chromatography using, as carrier,
- crosslinked dextrin crosslinked dextrin, styrene/divinylbenzene copolymers and other cross-linked polymers, and combinations thereof.
- the clathrate complexes of the invention may be prepared by any method known in the art for the
- a cyclodextrin derivative dissolved in water or in an organic solvent miscible with water may be added to a physiologically active compound (drug) dissolved in an organic solvent which is miscible with water.
- a physiologically active compound drug
- the desired product is obtained by concentrating the mixture under reduced pressure or leaving it to be cooled.
- the mixing ratio of organic solvent with water may be suitably varied according to the solubilities of the starting materials and products.
- drugs which may be complexed with the cyclodextrin derivatives include diphenyl hydantoin, adiphenine, allobarbital, aminobenzoic acid,
- betamethasone betamethasone 17-valerate, bromobenzoic acid, bromoisovalerylurea, butyl-p-aminobenzoate, chloralhydrate, chlorambucil, chloramphenicol,
- chlorobenzoic acid chlorpromazine, cinnamic acid, clofibrate, coenzyme A, cortisone, cortisone acetate, cyclobarbital, cyclohexyl anthranilate, deoxycholic acid, dexamethasone, dexamethasone acetate, diazepam, digitoxon, digoxin, estradiol, flufenamic acid, fluocinolone acetonide, 5-fluorouracil, flurbiprofen, griseofulvin, guaiazulene, hydrocortisone,
- phenobarbitone phenyl-butyric acid, phenyl-valeric acid, phenytoin, prednisolone, prednisolone acetate, progesterone, propylparaben, proscillaridin,
- prostaglandin A series prostaglandin B series,
- prostaglandin E series prostaglandin F series
- quinolone antimicrobials reserpine, spironolactone, sulfacetamide sodium, sulphonamide, testosterone, thalidomide, thiamine dilaurylsulphate, thiamphenicol- palmitate, thiopental, triamcinolone, vitamin A, vitamin D3, vitamin E, vitamin K3, and warfarin.
- the drug may be dissolved in water or an organic solvent (either miscible or immiscible with water).
- Convenient solvents include for example diethylether, tetrahydrofuran, dioxane, acetone, dimethylsulfoxide, dimethylformamide and lower aliphatic alcohols.
- the drug is dissolved in either water or a mixture of water and a water-miscible solvent such as methanol or ethanol.
- the drug may also be suspended in water.
- the complex may be isolated by any suitable technique for example
- Cyclodextrin inclusion complexes may also be produced by physicially grinding or kneading the cyclodextrin and the guest molecule with or without a small amount of solvent.
- the ratio of cyclodextrin derivative to drug used to prepare the clathrate complexes of the invention may be any convenient ratio but conveniently the
- cyclodextrin derivative is used in a molar excess.
- the benefits derived from the invention may be obtained by having the molar ratio of cyclodextrin derivative to drug in the range of 10:1 to 1:10
- Complexes are conveniently obtained containing up to 20% w/w of the drug.
- an excess of the cyclodextrin derivative present for example complexes containing in the order of 0.1 to 10% by weight of the drug, particularly in the range 0.5 to 0.2% by weight.
- the clathrate complexes of the invention provide a more convenient way of administering the drugs, the cyclodextrin acting merely as a solubilizing agent without altering the therapeutic behavior of the drug in any way.
- the invention thus also provides an inclusion complex as defined herein for use in human or
- the complex for use as a
- composition may presented as a pharmaceutical formulation.
- the invention therefore provides in a further aspect a pharmaceutical formulation comprising an inclusion complex of a drug with a cyclodextrin
- the pharmaceutical formulation will be in unit dosage form. Each unit dose will conveniently contain that amount of drug normally incorporated into a unit dose of such drug in the absence of a cyclodextrin.
- the pharmaceutical formulations may be any formulation in which the inclusion complexes may be administered and include those suitable for oral, intranasal, intraoccular or parenteral (including intramuscular and intravenous) administration.
- the formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of
- All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
- compositions suitable for oral administration wherein the carrier is a solid are most preferably presented as unit dose formulations such as boluses, capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
- a tablet may be made by compression or molding,
- Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding an inert liquid diluent. Tablets may be optionally coated and, if uncoated, may
- Capsules may be prepared by filling the active compound, either alone or in
- Cachets are analogous to capsules wherein the active ingredient together with any accessory
- ingredient(s) is sealed in a rice paper envelope.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and
- disintegrating agents for example maize starch, or alginic acid
- binding agents for example starch, gelatin or acacia
- lubricating agents for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known
- a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be
- the present invention also provides the complexes of the present invention in pharmaceutical formulations exhibiting sustained release of a drug.
- Pharmaceutical formulations exhibiting sustained release of a drug are generally known.
- Such formulations include devices made of inert polymers or biodegradable poly-acids in which the active ingredient (the present complex) is either dispersed, covalently linked via labile bonds, or stored as a reservoir between polymer membranes. Sustained release is achieved through diffusion of the active ingredient through the polymer matrix or
- Sustained release may also be presented by
- Osmotic pumps consist of a reservoir of solution or suspension of active ingredient (i.e., the present complex) surrounded by a semipermeable membrane
- the cyclodextrin derivatives of the invention act as drug solubilizing agents in these systems.
- the present cyclodextrin derivatives can also act as osmotic driving agents providing potential for the influx of water in such systems.
- compositions suitable for oral administration wherein the carrier is liquid may conveniently be presented as a solution in an aqueous liquid or a non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.
- Pharmaceutical formulations suitable for parenteral administration are conveniently presented in unit dose or multi-dose containers which are sealed after introduction of the formulation unit required for use.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example arachis oil, peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example arachis oil, peanut oil, liquid paraffin or olive oil.
- the pharmaceutical formulations described above may include, as
- one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants,
- preservatives including anti-oxidants and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
- the compounds of the present invention may be administered orally, topically, intranasally, intraoccularly, parenterally, by
- parenteral includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
- warm-blooded animals such as mice, rats, horses, dogs, cats, etc.
- the compounds of the invention are effective in the treatment of humans.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the
- Such excipients are suspending agents, for example sodium
- polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally
- phosphatide for example, lecithin, or
- condensation products of an alkylene oxide with fatty acids for example of polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example
- heptadecaethyleneoxycetanol or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol mono-oleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example
- the aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachls oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oil suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral
- compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerin, glycerin, glycerin, glycerin, glycerin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol
- compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oils, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soya bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan mono-oleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan mono-oleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with
- sweetening agents for example glycerol, sorbitol or sucrose.
- Such formulations may also contain a
- compositions may be in the form of a sterile injectable preparation, for example as a sterile injectable aqueous or oleagenous
- This suspension may be formulated
- injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- administration of humans may contain from 1.0 to 750 mg. of active agent compounded with an appropriate and convenient amount of carrier material which may vary vary from about 5 to about 95 weight percent of the total composition.
- Unit dosage forms will generally contain between from about 1 to about 500 mg. of active ingredient.
- compositions containing inclusion complexes may be administered at dosage levels and dosage intervals required to achieve the desired pharmacologic response normally associated with the drug and the disease state in absence of the
- the diasylate was concentrated by ultrafiltration and placed on.an ion-exchange column composed of 50 grams A-25 DEAE-Sephadex packed in a 1.25 inch i.d. glass column. Unreacted ⁇ -cyclodextrin was removed by elution with distilled water. The mono-substituted sulfobutyl ether of ⁇ -cyclodextrin was isolated by elution with 0.1 N sodium hydroxide. The effluent fraction containing the mono-substituted derivative was ultrafiltered to remove any residual salts. The pH of the retentate was adjusted to neutrality and
- Example 3 The processes of Example 3 were varied with regard to reactants and molar ratios to obtain cyclodextrin
- Figure 1 provides data for the underivatized cyclodextrin compound, the hydroxypropyl derivative, the sulfobutyl derivative of the invention, and the sulfopropyl derivative of the invention.
- the sulfoalkyl cyclodextrin derivatives of the invention exhibited no observable toxic effects in male mice over a 30 day period following intraperitoneal of 5.49 ⁇ 10 -3 mol/Kg.
- This dose is equivalent to 7.1 gm/Kg for the monosulfoalkyl derivatives, 12.3 gm/Kg for the
- Plasma urea nitrogen levels are an indicator of kidney function with higher levels indicating renal damage.
- the data in Table 1 indicates that the
- sulfoalkyl cyclodextrin derivatives of the invention do not cause increased plasma urea nitrogen levels in mice as compared to the underivatized parent compound
- the mono substituted derivatives caused about the same amount of membrane disruption as the hydroxypropyl derivative.
- solubility of digoxin is ⁇ 216 mg/mL for the present sulfobutyl derivatives as compared to ⁇ 80 mg/mL for the hydroxypropyl derivative.
- the value of 45.0 mg/mL reported in US 4,727,064 was for a hydroxypropyl derivative with a different degree of substitution than the hydroxypropyl derivative used herein for
- oral formulations can tolerate higher amounts of ⁇ -cyclodextrin without compromising toxicity concerns.
- Useful tolerated levels of ⁇ -cyclodextrin still depend upon a proper balancing of other characteristics, including
- aqueous solubility particularly intrinsic aqueous solubility.
- the maximum water solubility of any modified cyclodextrin dictates the limits of its usefulness in solubilizing drug substances.
- Table 6 shows the results of a comparison of the water solubility of various
- sulfoalkylether derivatives generated by the present invention which have been doped to contain ⁇ 0.7 to 25% by weight residual ⁇ -cyclodextrin versus the water solubility of the derivatives generated by the method described in U.S. Patent 3,426,011 to Parmerter which contain from 69-82% by weight residual ⁇ -cyclodextrin.
- Figures 11-13 graphically show the solubility characteristics of several drugs with the derivatives of the present invention containing varying amounts of ⁇ -cyclodextrin.
- Figures 1 and 12 show the results of solubility studies with two different drugs,
- Figure 13 reports the results of solubility characteristics for naproxen for compositions of the sulfobutyl ether derivatives of the invention with various amounts of ⁇ -cyclodextrin. This study
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019940700951A KR100279111B1 (en) | 1992-07-27 | 1993-07-26 | Cyclodextrin derivatives with increased water solubility and uses thereof |
TJ96000377A TJ275B (en) | 1992-07-27 | 1993-07-26 | Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof |
MD96-0306A MD1813C2 (en) | 1992-07-27 | 1993-07-26 | Purified cyclodextrin derivatives of sulphoalkyl ethers or mixtures thereof, clathrate complex of cyclodextrin derivatives with medicamental content and pharmaceutical composition |
DK93918302T DK0620828T4 (en) | 1992-07-27 | 1993-07-26 | Cyclodextrin derivatives with increased water solubility and use thereof |
AU47799/93A AU672814B2 (en) | 1992-07-27 | 1993-07-26 | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
AT93918302T ATE217325T1 (en) | 1992-07-27 | 1993-07-26 | CYCLODEXTRINE DERIVATIVES WITH INCREASED WATER SOLUBILITY AND THE USE THEREOF |
EP93918302A EP0620828B2 (en) | 1992-07-27 | 1993-07-26 | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
DE69331900T DE69331900T3 (en) | 1992-07-27 | 1993-07-26 | CYCLODEXTRIN DERIVATIVES WITH INCREASED WATER LIQUIDITY AND THEIR USE |
JP50467894A JP3393253B2 (en) | 1992-07-27 | 1993-07-26 | Highly water-soluble cyclodextrin derivatives and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/918,702 US5376645A (en) | 1990-01-23 | 1992-07-27 | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US07/918,702 | 1992-07-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994002518A1 true WO1994002518A1 (en) | 1994-02-03 |
WO1994002518A9 WO1994002518A9 (en) | 1994-03-03 |
Family
ID=25440795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/006880 WO1994002518A1 (en) | 1992-07-27 | 1993-07-26 | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
Country Status (16)
Country | Link |
---|---|
US (1) | US5376645A (en) |
EP (1) | EP0620828B2 (en) |
JP (1) | JP3393253B2 (en) |
KR (1) | KR100279111B1 (en) |
AT (1) | ATE217325T1 (en) |
AU (1) | AU672814B2 (en) |
CA (1) | CA2119154C (en) |
DE (1) | DE69331900T3 (en) |
DK (1) | DK0620828T4 (en) |
ES (1) | ES2176206T5 (en) |
GE (1) | GEP19991649B (en) |
MD (1) | MD1813C2 (en) |
PT (1) | PT620828E (en) |
RU (1) | RU2113442C1 (en) |
TJ (1) | TJ275B (en) |
WO (1) | WO1994002518A1 (en) |
Cited By (296)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0709099A3 (en) * | 1994-09-28 | 1996-07-24 | Senju Pharma Co | An aqueous nasal suspension comprising cyclodextrin |
WO1996041646A2 (en) * | 1995-06-13 | 1996-12-27 | Dyer, Alison, Margaret | Pharmaceutical compositions containing lornoxicam and cyclodextrin |
WO1998047518A1 (en) * | 1997-04-17 | 1998-10-29 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Use of cholesterol-lowering agents to influence signal transduction processes in the cell membrane and in the prophylaxis or treatment of prion-associated diseases or alzheimer's disease |
WO1998050077A1 (en) * | 1997-05-05 | 1998-11-12 | Cydex Inc. | Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent |
WO1998056422A1 (en) * | 1997-06-13 | 1998-12-17 | The University Of Kansas | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
WO1998058677A1 (en) * | 1997-06-21 | 1998-12-30 | Pfizer Limited | Pharmaceutical formulations containing voriconazole |
EP0889056A2 (en) * | 1997-07-01 | 1999-01-07 | Pfizer Products Inc. | Process for making a cyclodextrin |
WO1999042111A1 (en) * | 1998-02-23 | 1999-08-26 | Cyclops, Ehf. | High-energy cyclodextrin complexes |
WO2000021503A1 (en) * | 1998-10-14 | 2000-04-20 | Adir Et Compagnie | Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin |
WO2000033885A1 (en) * | 1998-12-04 | 2000-06-15 | California Institute Of Technology | Supramolecular complexes containing therapeutic agents |
WO2000041704A1 (en) * | 1999-01-13 | 2000-07-20 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
WO2001000243A1 (en) * | 1999-06-29 | 2001-01-04 | Pfizer Limited | Pharmaceutical complex |
WO2001030391A2 (en) * | 1999-10-27 | 2001-05-03 | Farmarc Nederland Bv | Pharmaceutical composition containing midazolam |
US6232304B1 (en) | 1996-05-07 | 2001-05-15 | Pfizer Inc. | Inclusion complexes of aryl-heterocyclic salts |
WO2001072338A1 (en) * | 2000-03-28 | 2001-10-04 | Farmarc Nederland Bv | Alprazolam inclusion complexes and pharmaceutical compositions thereof |
US6350735B1 (en) | 1999-10-14 | 2002-02-26 | Pfizer Inc | Purine derivatives |
US6420557B1 (en) | 2000-07-28 | 2002-07-16 | Pfizer Inc. | Crystalline therapeutic agent |
US6448236B1 (en) | 1999-10-14 | 2002-09-10 | Pfizer Inc | Purine derivatives |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
WO2003002153A1 (en) * | 2001-06-28 | 2003-01-09 | Wyeth | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins |
WO2003002152A2 (en) * | 2001-06-29 | 2003-01-09 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
US6624158B2 (en) | 2000-09-15 | 2003-09-23 | Pfizer Inc | Purine derivatives |
WO2003080599A1 (en) | 2002-03-26 | 2003-10-02 | Novartis International Pharmaceutical Ltd. | Stable hydrate of a muscarinic receptor antagonist |
US6653339B2 (en) | 2001-08-15 | 2003-11-25 | Pfizer Inc. | Method of treating irritable bowel syndrome |
WO2003099288A1 (en) * | 2002-05-28 | 2003-12-04 | Taisho Pharmaceutical Co., Ltd. | Medicinal composition |
US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
WO2004024765A1 (en) | 2002-09-12 | 2004-03-25 | University Of Bath | Crystal structure of an angiotensin-converting enzyme (ace) and uses thereof |
US6753322B2 (en) | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
US6756392B2 (en) | 2002-02-11 | 2004-06-29 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
US6852746B2 (en) | 2001-12-06 | 2005-02-08 | Pfizer Inc | Crystalline drug form |
US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
US6900309B1 (en) | 1999-06-15 | 2005-05-31 | Pfizer Inc | Purine derivatives |
WO2005051293A2 (en) | 2003-11-21 | 2005-06-09 | Combinatorx, Incorporated | Methods and reagents for the treatment of inflammatory disorders |
US6914160B1 (en) | 2002-08-28 | 2005-07-05 | Pfizer Inc | Oxytocin inhibitors |
US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
US6949573B2 (en) | 2002-02-11 | 2005-09-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
US6962923B2 (en) | 1999-07-29 | 2005-11-08 | Pfizer Inc. | Pyrazole compositions |
US7109228B2 (en) | 2001-04-10 | 2006-09-19 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
WO2006097817A1 (en) | 2005-03-17 | 2006-09-21 | Pfizer Japan Inc. | N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain |
US7183294B2 (en) | 2003-03-14 | 2007-02-27 | Pfizer Inc. | Indole derivatives useful for the treatment of diseases |
US7220772B2 (en) | 2003-09-05 | 2007-05-22 | Pfizer, Inc. | Pyrazole derivatives |
US7230025B2 (en) | 2002-09-26 | 2007-06-12 | Pfizer, Inc. | Pyrazole derivatives |
WO2007072163A2 (en) | 2005-12-20 | 2007-06-28 | Pfizer Limited | Pyrimidine derivatives |
US7241810B2 (en) | 2004-03-23 | 2007-07-10 | Pfizer Inc | Formamide derivatives for the treatment of diseases |
US7244766B2 (en) | 2004-01-22 | 2007-07-17 | Pfizer Inc | Sulfonamide derivatives for the treatment of diseases |
US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
US7309790B2 (en) | 2003-10-03 | 2007-12-18 | Pfizer Inc | Chemical compounds |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
WO2008024914A2 (en) | 2006-08-23 | 2008-02-28 | Intellect Neurosciences Inc. | 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom |
US7348317B2 (en) | 2001-12-24 | 2008-03-25 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
US7351742B2 (en) | 2004-01-22 | 2008-04-01 | Pfizer Inc. | Sulfonamide derivatives for the treatment of diseases |
WO2008050199A2 (en) | 2006-10-23 | 2008-05-02 | Pfizer Japan Inc. | Substituted phenylmethyl bicyclocarboxyamide compounds |
US7368460B2 (en) | 2000-05-26 | 2008-05-06 | Pfizer, Inc. | Tropane derivatives useful in therapy |
US7375096B1 (en) | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
US7432299B2 (en) | 2002-12-13 | 2008-10-07 | Pfizer Inc. | Method of treatment for sexual dysfunction |
EP1990341A1 (en) | 2000-05-26 | 2008-11-12 | Pfizer Inc. | Triazolyl tropane derivatives as CCR5 modulators |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
WO2008147556A2 (en) | 2007-05-25 | 2008-12-04 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
EP2017259A2 (en) | 2005-12-21 | 2009-01-21 | Pfizer Products Inc. | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein |
US7511057B2 (en) | 2004-08-12 | 2009-03-31 | Pfizer Inc. | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors |
US7538134B2 (en) | 2005-06-15 | 2009-05-26 | Pfizer Inc. | Substituted arylpyrazoles |
US7538141B2 (en) | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
EP2070550A1 (en) | 2003-10-15 | 2009-06-17 | Combinatorx, Incorporated | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases |
US7557121B2 (en) | 2004-05-12 | 2009-07-07 | Pfizer Inc | Tetrahydronaphthyridine derivatives |
US7595329B2 (en) | 2004-06-15 | 2009-09-29 | Pfizer Inc | Benzimidazolone carboxylic acid derivatives |
US7598393B2 (en) | 2004-11-02 | 2009-10-06 | Pfizer Inc. | Sulfonyl benzimidazole derivatives |
US7618972B2 (en) | 2005-03-21 | 2009-11-17 | Pfizer Inc | Substituted triazole derivatives as oxytocin antagonists |
US7629358B2 (en) | 2004-03-17 | 2009-12-08 | Pfizer Inc | Compounds useful for the treatment of diseases |
US7642350B2 (en) | 2005-05-04 | 2010-01-05 | Pfizer Limited | Purine derivatives |
US7645786B2 (en) | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
US7659394B2 (en) | 2004-04-30 | 2010-02-09 | Pfizer Inc | Substituted morpholine compounds for the treatment of central nervous system disorders |
EP2156863A2 (en) | 2003-09-12 | 2010-02-24 | Pfizer Limited | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
US7671196B2 (en) | 2005-07-26 | 2010-03-02 | Wyeth Llc | Diazepinoquinolines, synthesis thereof, and intermediates thereto |
EP2163253A1 (en) | 2008-09-15 | 2010-03-17 | Charité-Universitätsmedizin Berlin | Extracts from the plant hornstedtia scyphifera and immnunosuppressive effects thereof |
US7687533B2 (en) | 2004-03-18 | 2010-03-30 | Pfizer Inc. | N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides |
EP2181995A2 (en) | 2003-09-03 | 2010-05-05 | Glaxo Group Limited | Salts and crystalline form of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-sufanyl)-acetate |
WO2010058858A1 (en) | 2008-11-21 | 2010-05-27 | ラクオリア創薬株式会社 | Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity |
US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
EP2196201A2 (en) | 2002-12-13 | 2010-06-16 | Warner-Lambert Company LLC | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms |
US7744890B2 (en) | 2006-10-12 | 2010-06-29 | Wyeth Llc | Methods and compositions with reduced opalescence |
WO2010080528A1 (en) | 2008-12-17 | 2010-07-15 | Genentech, Inc. | Hepatitis c virus combination therapy |
WO2010079443A1 (en) | 2009-01-12 | 2010-07-15 | Pfizer Limited | Sulfonamide derivatives |
WO2010082019A1 (en) | 2009-01-14 | 2010-07-22 | Novacta Biosystems Limited | Actagardine derivatives, and pharmaceutical use thereof |
WO2010082018A1 (en) | 2009-01-14 | 2010-07-22 | Novacta Biosystems Limited | Deoxyactagardine derivatives |
WO2010089544A1 (en) | 2009-02-04 | 2010-08-12 | Novacta Biosystems Limited | Actagardine derivatives |
US7776885B2 (en) | 2003-09-03 | 2010-08-17 | Pfizer, Inc. | Benzimidazolone compounds having 5-HT4 receptor agonistic activity |
US7781427B2 (en) | 2004-11-05 | 2010-08-24 | Wyeth Llc | Process for preparing quinoline compounds and products obtained therefrom |
WO2010103070A2 (en) | 2009-03-12 | 2010-09-16 | Charité - Universitätsmedizin Berlin | Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity |
EP2233502A1 (en) | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
WO2010136940A1 (en) | 2009-05-29 | 2010-12-02 | Pfizer Limited | Novel glucocorticoid receptor agonists |
US7858643B2 (en) | 2004-08-26 | 2010-12-28 | Agouron Pharmaceuticals, Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
EP2266563A1 (en) | 2009-06-11 | 2010-12-29 | Charité-Universitätsmedizin Berlin (Charité) | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
EP2277513A2 (en) | 2003-04-25 | 2011-01-26 | Pfizer Inc. | Treatment of incontinence with 5htc2 agonists |
WO2011077313A1 (en) | 2009-12-22 | 2011-06-30 | Pfizer Inc. | Piperidinecarboxamides as mpges - 1 inhibitors |
WO2011079051A1 (en) | 2009-12-23 | 2011-06-30 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
EP2341146A2 (en) | 2001-07-05 | 2011-07-06 | Imperial College Innovations Limited | Method for determining chromatin structure |
WO2011083387A1 (en) | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
US7989416B2 (en) | 2006-01-17 | 2011-08-02 | Novacta Biosystems Limited | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. Liguriae |
WO2011095768A1 (en) | 2010-02-02 | 2011-08-11 | Novacta Biosystems Limited | Lantibiotic salts |
WO2011095769A1 (en) | 2010-02-02 | 2011-08-11 | Novacta Biosystems Limited | Actagardine derivatives, and pharmaceutical use thereof |
WO2011104649A1 (en) | 2010-02-25 | 2011-09-01 | Pfizer Limited | Peptide analogues |
US8044052B2 (en) | 2006-10-18 | 2011-10-25 | Pfizer Inc. | Biaryl ether urea compounds |
EP2380566A2 (en) | 2006-09-15 | 2011-10-26 | Stevia APS | Treatment of insulin resistance or diseases associated with insulin resistance using steviol or isosteviol |
WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
US8058344B2 (en) | 2002-04-19 | 2011-11-15 | Imperial Innovations Ltd | Glycodendrimers having biological activity |
US8076293B2 (en) | 2005-04-19 | 2011-12-13 | Gabriel Stavros Panayi | Use of BiP or a variant, homologue, derivative or fragment thereof in the manufacture of a medicament for the prevention or treatment of bone loss or bone resorption |
EP2395077A1 (en) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
WO2011154871A1 (en) | 2010-06-10 | 2011-12-15 | Pfizer Limited | Hepatitis c virus inhibitors |
WO2012004706A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
WO2012004714A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
WO2012007861A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
WO2012007877A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012007883A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
WO2012007869A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012007868A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012020220A1 (en) | 2010-08-11 | 2012-02-16 | Novacta Biosystems Limited | Compounds |
WO2012020222A1 (en) | 2010-08-11 | 2012-02-16 | Novacta Biosystems Limited | Compounds |
WO2012020221A1 (en) | 2010-08-11 | 2012-02-16 | Novacta Biosystems Limited | Compounds |
WO2012020219A2 (en) | 2010-08-11 | 2012-02-16 | Novacta Biosystems Limited | Formulations for infusion of type b lantibiotics |
WO2012025745A1 (en) | 2010-08-24 | 2012-03-01 | Imperial Innovations Limited | Glycodendrimers of polypropyletherimine |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
WO2012066442A1 (en) | 2010-11-15 | 2012-05-24 | Pfizer Limited | Inhibitors of hiv replication |
WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
US8252276B2 (en) | 2002-09-06 | 2012-08-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
WO2012120398A1 (en) | 2011-03-04 | 2012-09-13 | Pfizer Limited | Aryl substituted carboxamide derivatives as trpm8 modulators |
WO2012137089A1 (en) | 2011-04-05 | 2012-10-11 | Pfizer Limited | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
WO2012148548A1 (en) | 2011-02-25 | 2012-11-01 | Takeda Pharmaceutical Company Limited | N-substituted oxazinopteridines and oxazinopteridinones |
WO2012157288A1 (en) | 2011-05-18 | 2012-11-22 | Raqualia Pharma Inc. | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid |
US8323664B2 (en) | 2006-07-25 | 2012-12-04 | The Secretary Of State For Defence | Live vaccine strains of Francisella |
US8329644B2 (en) | 2007-07-18 | 2012-12-11 | Novacta Biosystems Limited | Lantibiotic-based compounds having antimicrobial activity |
WO2012171561A1 (en) | 2011-06-15 | 2012-12-20 | Synthon Bv | Stabilized voriconazole composition |
WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
WO2013008123A1 (en) | 2011-07-13 | 2013-01-17 | Pfizer Limited | Enkephalin analogues |
WO2013014567A1 (en) | 2011-07-27 | 2013-01-31 | Pfizer Limited | Indazoles |
WO2013017136A1 (en) | 2011-08-02 | 2013-02-07 | Pensieve Biosciences Cyprus Limited | Treatment of cognitive impairment |
WO2013017989A1 (en) | 2011-08-02 | 2013-02-07 | Pfizer Inc. | Crizotinib for use in the treatment of cancer |
WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
WO2013057722A1 (en) | 2011-10-21 | 2013-04-25 | Pfizer Limited | New salt and medical use |
WO2013061297A1 (en) | 2011-10-28 | 2013-05-02 | Pfizer Limited | Pyridazine Derivatives Useful in Therapy |
WO2013061205A2 (en) | 2011-10-26 | 2013-05-02 | Pfizer Limited | Chemical compounds |
US8466166B2 (en) | 2006-09-21 | 2013-06-18 | Raqualia Pharma Inc. | Benzimidazole derivatives as selective acid pump inhibitors |
WO2013088315A1 (en) | 2011-12-15 | 2013-06-20 | Pfizer Limited | Sulfonamide derivatives |
WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
WO2013102826A1 (en) | 2012-01-04 | 2013-07-11 | Pfizer Limited | N-aminosulfonyl benzamides |
US8486935B2 (en) | 2007-09-05 | 2013-07-16 | Rigel Pharmaceuticals, Inc. | Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine |
US8497365B2 (en) | 2007-01-24 | 2013-07-30 | Mark E. Davis | Cyclodextrin-based polymers for therapeutics delivery |
WO2013110945A1 (en) | 2012-01-26 | 2013-08-01 | Imperial Innovations Ltd | Methods of treating pain by inhibition of vgf activity |
WO2013114250A1 (en) | 2012-02-03 | 2013-08-08 | Pfizer Inc. | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
US8518952B2 (en) | 2008-08-06 | 2013-08-27 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors |
WO2013132376A1 (en) | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
US8575094B2 (en) | 2007-07-18 | 2013-11-05 | Novacta Biosystems Limited | Use of type-B lantibiotic-based compounds having antimicrobial activity |
US8609108B2 (en) | 2009-04-14 | 2013-12-17 | The Secretary Of State For Defence | Gamma-glutamyl transpeptidase attenuated Francisella |
WO2014011568A1 (en) | 2012-07-10 | 2014-01-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives which act as pi3k inhibitors |
US8653049B2 (en) | 2008-03-17 | 2014-02-18 | Imuthes Limited | Normuramyl glycopeptide compounds |
WO2014039831A1 (en) | 2012-09-07 | 2014-03-13 | Takeda Pharmaceutical Company Limited | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES |
WO2014049488A1 (en) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
WO2014053967A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors |
WO2014053968A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
WO2014053965A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Tropomyosin-related kinase inhibitors |
US8703099B2 (en) | 2005-02-24 | 2014-04-22 | Dr Pharma Nova, Llc | Registry method and control system for DEA schedule II-V medicines |
WO2014072881A1 (en) | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2014072882A1 (en) | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds as dopamine d1 ligands |
WO2014087298A1 (en) | 2012-12-03 | 2014-06-12 | Pfizer Inc. | Novel selective androgen receptor modulators |
WO2014091368A1 (en) | 2012-12-14 | 2014-06-19 | Pfizer Limited | Imidazopyridazine derivatives as gabaa receptor modulators |
WO2014097041A1 (en) | 2012-12-21 | 2014-06-26 | Pfizer Inc. | Aryl and heteroaryl fused lactams |
US8796006B2 (en) | 2006-01-10 | 2014-08-05 | University Of Bath | Crystal structure of the N-terminal domain of angiotensin converting enzyme and uses thereof |
WO2014128588A1 (en) | 2013-02-21 | 2014-08-28 | Pfizer Inc. | Solid forms of a selective cdk4/6 inhibitor |
US8835407B2 (en) | 2009-05-13 | 2014-09-16 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
US8846901B2 (en) | 2005-10-26 | 2014-09-30 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
EP2784083A1 (en) | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
US8853236B2 (en) | 2007-04-27 | 2014-10-07 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
WO2014164558A1 (en) | 2013-03-11 | 2014-10-09 | Takeda Pharmaceutical Company Limited | Pyridinyl and fused pyridinyl triazolone derivatives |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
WO2014170793A1 (en) | 2013-04-19 | 2014-10-23 | Pfizer Limited | Sulfonamides for the treatment of gout |
WO2014170792A1 (en) | 2013-04-19 | 2014-10-23 | Pfizer Limited | Sulfonamide derivatives as urat-1 inhibitors |
WO2014181213A1 (en) | 2013-05-10 | 2014-11-13 | Pfizer Inc. | Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide |
WO2014207601A1 (en) | 2013-06-27 | 2014-12-31 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
WO2015050989A2 (en) | 2013-10-01 | 2015-04-09 | Cs Therapeutics Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
US9012180B2 (en) | 2007-03-02 | 2015-04-21 | Wyeth Llc | Use of copper and glutamate in cell culture for production of polypeptides |
WO2015092610A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2015106012A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
WO2015106014A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
KR20150085515A (en) | 2012-11-21 | 2015-07-23 | 라퀄리아 파마 인코포레이티드 | Polymorph forms |
CN104971355A (en) * | 2014-04-02 | 2015-10-14 | 上海现代药物制剂工程研究中心有限公司 | Rivaroxaban-containing composition and preparation method thereof |
WO2015159175A1 (en) | 2014-04-15 | 2015-10-22 | Pfizer Inc. | Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety |
WO2015162515A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2015162518A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2015162516A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2015166366A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
WO2015170218A1 (en) | 2014-05-07 | 2015-11-12 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
WO2015173684A1 (en) | 2014-05-15 | 2015-11-19 | Pfizer Inc. | Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile |
WO2015173683A1 (en) | 2014-05-14 | 2015-11-19 | Pfizer Inc. | Pyrazolopyridines and pyrazolopyrimidines |
WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
WO2015181797A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Benzenesulfonamides useful as sodium channel inhibitors |
WO2015189744A1 (en) | 2014-06-12 | 2015-12-17 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
WO2015193768A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
WO2015193765A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Substituted dihydroisoquinolinone compounds |
WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
WO2016009296A1 (en) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2016009303A1 (en) | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors |
WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
WO2016034971A1 (en) | 2014-09-04 | 2016-03-10 | Pfizer Limited | Sulfonamides derivatives as urat1 inhibitors |
WO2016044433A2 (en) | 2014-09-16 | 2016-03-24 | Biopharma Works | Metformin derivatives |
WO2016067143A1 (en) | 2014-10-28 | 2016-05-06 | Pfizer Inc. | N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels |
US9364458B2 (en) | 2013-07-08 | 2016-06-14 | Abbvie Inc. | Stabilized pharmaceutical dosage forms comprising atrasentan |
WO2016100778A1 (en) | 2014-12-19 | 2016-06-23 | Takeda Pharmaceutical Company Limited | Fumagillol derivatives |
WO2016097918A1 (en) | 2014-12-18 | 2016-06-23 | Pfizer Inc. | Pyrimidine and triazine derivatives and their use as axl inhibitors |
WO2016116628A1 (en) | 2015-01-22 | 2016-07-28 | Phytoplant Research S.L. | Methods of purifying cannabinoids, compositions and kits thereof |
EP3050574A1 (en) | 2015-01-28 | 2016-08-03 | Universite De Bordeaux | New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease |
US9533989B2 (en) | 2012-09-18 | 2017-01-03 | Ziarco Pharma Ltd. | Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors |
WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
WO2017098367A1 (en) | 2015-12-10 | 2017-06-15 | Pfizer Limited | 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain |
WO2017111179A1 (en) | 2015-12-24 | 2017-06-29 | Takeda Pharmaceutical Company Limited | Cocrystal, production method thereof, and medicament containing cocrystal |
WO2017120429A1 (en) | 2016-01-07 | 2017-07-13 | CS Pharmasciences, Inc. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
WO2017119732A1 (en) | 2016-01-08 | 2017-07-13 | Samsung Electronics Co., Ltd. | Electronic device and operating method thereof |
WO2017122116A1 (en) | 2016-01-15 | 2017-07-20 | Pfizer Inc. | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
WO2017156341A1 (en) | 2016-03-09 | 2017-09-14 | Beijing Percans Oncology Co. Ltd. | Tumor cell suspension cultures and related methods |
WO2017173111A1 (en) * | 2016-03-31 | 2017-10-05 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
US9827324B2 (en) | 2003-12-31 | 2017-11-28 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
WO2017212385A1 (en) | 2016-06-06 | 2017-12-14 | Pfizer Inc. | Substituted carbonucleoside derivatives useful as anticancer agents |
WO2018020358A1 (en) | 2016-07-29 | 2018-02-01 | Pfizer Inc. | Cyclic peptides as c5 a receptor antagonists |
WO2018033815A1 (en) | 2016-08-15 | 2018-02-22 | Pfizer Inc. | Pyridopyrimdinone cdk2/4/6 inhibitors |
WO2018096510A1 (en) | 2016-11-28 | 2018-05-31 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
US9988370B2 (en) | 2014-05-20 | 2018-06-05 | Raqualia Pharma Inc. | Benzisoxazole derivative salt |
WO2018134695A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors |
WO2018134698A1 (en) | 2017-01-23 | 2018-07-26 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
US10117940B2 (en) | 2004-04-23 | 2018-11-06 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
WO2018232202A1 (en) | 2017-06-15 | 2018-12-20 | Takeda Pharmaceutical Company Limited | Tetrahydropyridopyrazine modulators of gpr6 |
WO2019051469A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
WO2019060850A1 (en) | 2017-09-25 | 2019-03-28 | Takeda Pharmaceutical Company Limited | N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivatives useful as hif prolyl hydroxylase inhibitors |
WO2019145552A1 (en) | 2018-01-29 | 2019-08-01 | Phytoplant Research S.L | Methods of purifying cannabinoids using liquid:liquid chromatography |
WO2019150305A1 (en) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents |
WO2019155399A1 (en) | 2018-02-09 | 2019-08-15 | Pfizer Inc. | Tetrahydroquinazoline derivatives useful as anticancer agents |
WO2019169153A1 (en) | 2018-03-01 | 2019-09-06 | Takeda Pharmaceutical Company Limited | Piperidinyl-3-(aryloxy)propanamides and propanoates |
US10428104B2 (en) | 2015-02-24 | 2019-10-01 | Pfizer Inc. | Substituted nucleoside derivatives useful as anticancer agents |
WO2019207463A1 (en) | 2018-04-26 | 2019-10-31 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
WO2019243823A1 (en) | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Azaheterocyclic small molecule modulators of human sting |
US10538542B2 (en) | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
WO2020016710A1 (en) | 2018-07-19 | 2020-01-23 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
WO2020076728A1 (en) | 2018-10-08 | 2020-04-16 | Takeda Pharmaceutical Company Limited | SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR |
US10624972B2 (en) | 2015-03-13 | 2020-04-21 | Endocyte, Inc. | Conjugates for treating diseases |
WO2020100027A1 (en) | 2018-11-15 | 2020-05-22 | Pfizer Inc. | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer |
WO2020109994A1 (en) | 2018-11-29 | 2020-06-04 | Pfizer Inc. | Pyrazoles as modulators of hemoglobin |
WO2020152557A1 (en) | 2019-01-23 | 2020-07-30 | Pfizer Inc. | Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative |
WO2020157652A2 (en) | 2019-01-31 | 2020-08-06 | Pfizer Inc. | Cdk2 inhibitors |
WO2020198053A1 (en) | 2019-03-22 | 2020-10-01 | Takeda Pharmaceutical Company Limited | 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases |
US10793572B2 (en) | 2014-09-29 | 2020-10-06 | The Provost Fellows Foundation Scholars And The Other Members Of Board Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
WO2020223255A1 (en) | 2019-04-29 | 2020-11-05 | Solent Therapeutics, Llc | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 |
WO2021009676A1 (en) | 2019-07-17 | 2021-01-21 | Pfizer Inc. | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits |
WO2021014415A2 (en) | 2019-07-25 | 2021-01-28 | Curadev Pharma Pvt. Ltd. | Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2) |
WO2021055326A1 (en) | 2019-09-16 | 2021-03-25 | Takeda Pharmaceutical Company Limited | Azole-fused pyridazin-3(2h)-one derivatives |
WO2021059136A1 (en) | 2019-09-25 | 2021-04-01 | Pfizer Inc. | Polyheterocyclic modulators of sting (stimulator of interferon genes) |
GB202104609D0 (en) | 2021-03-31 | 2021-05-12 | Sevenless Therapeutics Ltd | New Treatments for Pain |
WO2021161230A1 (en) | 2020-02-12 | 2021-08-19 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
WO2021202781A1 (en) | 2020-03-31 | 2021-10-07 | Takeda Pharmaceutical Company Limited | N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as sstr4 agonists |
WO2021202775A1 (en) | 2020-03-31 | 2021-10-07 | Takeda Pharmaceutical Company Limited | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists |
WO2021205363A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors |
WO2021220185A1 (en) | 2020-05-01 | 2021-11-04 | Pfizer Inc. | Azalactam compounds as hpk1 inhibitors |
WO2021225968A1 (en) | 2020-05-04 | 2021-11-11 | Takeda Pharmaceutical Company Limited | Luminally-acting n-(piperidin-4-yl)benzamide derivatives |
WO2021224818A1 (en) | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
WO2022003575A1 (en) | 2020-06-30 | 2022-01-06 | Array Biopharma Inc. | Her2 mutation inhibitors |
WO2022013692A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride |
WO2022013691A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol |
US11229652B2 (en) | 2014-09-29 | 2022-01-25 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Treatments for autoimmune disease |
WO2022018667A1 (en) | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
WO2022023438A1 (en) | 2020-07-29 | 2022-02-03 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Compounds |
WO2022023433A1 (en) | 2020-07-29 | 2022-02-03 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Compounds |
WO2022066917A1 (en) | 2020-09-23 | 2022-03-31 | Takeda Pharmaceutical Company Limited | 3-(6-aminopyridin-3-yl)benzamide derivatives as ripk2 inhibitors |
RU2776671C2 (en) * | 2019-07-11 | 2022-07-22 | Общество С Ограниченной Ответственностью "Научно-Исследовательский Центр "Парк Активных Молекул" (Ооо "Ниц Пам") | Use of clathrate complex of 20-hydroxyecdysone with arabinogalactan for normalization of metabolism, increase in non-specific resistance, growth and development of animals |
US11426397B2 (en) | 2017-03-26 | 2022-08-30 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 |
WO2022195462A1 (en) | 2021-03-18 | 2022-09-22 | Pfizer Inc. | Modulators of sting (stimulator of interferon genes) |
WO2022207673A1 (en) | 2021-03-31 | 2022-10-06 | Sevenless Therapeutics Limited | Sos1 inhibitors and ras inhibitors for use in the treatment of pain |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
WO2022214869A2 (en) | 2021-04-07 | 2022-10-13 | Lifearc | Ulk1/2 inhibitors and their use thereof |
WO2022259091A1 (en) | 2021-06-10 | 2022-12-15 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd | Purification of sulfobutylated cyclodextrins with specific ion exchange resins |
WO2022269531A1 (en) | 2021-06-26 | 2022-12-29 | Array Biopharma Inc. | Her2 mutation inhibitors |
US11571423B2 (en) | 2017-06-22 | 2023-02-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
WO2023017452A1 (en) | 2021-08-11 | 2023-02-16 | Curadev Pharma Pvt. Ltd. | Small molecule urea derivatives as sting antagonists |
WO2023017451A1 (en) | 2021-08-11 | 2023-02-16 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
WO2023099072A1 (en) | 2021-12-01 | 2023-06-08 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Compounds |
US11773132B2 (en) | 2017-08-30 | 2023-10-03 | Beijing Xuanyi Pharmasciences Co., Ltd. | Cyclic di-nucleotides as stimulator of interferon genes modulators |
EP4252856A2 (en) | 2016-12-20 | 2023-10-04 | Oligomerix, Inc. | Novel quinazolinones that inhibit the formation of tau oligomers and their method of use |
WO2023187677A1 (en) | 2022-03-30 | 2023-10-05 | Takeda Pharmaceutical Company Limited | N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives |
WO2023194964A1 (en) | 2022-04-07 | 2023-10-12 | Takeda Pharmaceutical Company Limited | Fused pyridazine derivatives as nlrp3 inhibitors |
WO2024023727A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Novel acc inhibitors |
WO2024033845A1 (en) | 2022-08-10 | 2024-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2024074827A1 (en) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | New treatments for pain |
Families Citing this family (275)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA959469B (en) * | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
US5468502A (en) * | 1994-12-20 | 1995-11-21 | American Home Products Corporation | Ibuprofen enhancing solvent system |
CA2252374C (en) | 1996-04-19 | 2007-08-07 | Alpha Therapeutic Corporation | A process for viral inactivation of lyophilized blood proteins |
US5906981A (en) * | 1996-06-04 | 1999-05-25 | Troy Corporation | Halopropargyl inclusion complexes |
DE69725704T2 (en) * | 1996-08-09 | 2004-05-13 | Alcon Manufacturing Ltd., Fort Worth | PRESERVATION SYSTEMS FOR MEDICINAL PRODUCTS CONTAINING CYCLODEXTRINE |
RU2216549C2 (en) * | 1997-11-07 | 2003-11-20 | Дайити Фармасьютикал Ко., Лтд. | Piperazine-cyclodextrin complex and medicinal agent containing indicated complex |
EP1109581A1 (en) * | 1998-09-02 | 2001-06-27 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
SK9602001A3 (en) | 1999-01-21 | 2002-06-04 | Bristol Myers Squibb Co | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method |
DE60136926D1 (en) * | 2000-05-02 | 2009-01-22 | Theravance Inc | COMPOSITION CONTAINING A CYCLODEXTRIN AND A GLYCOPEPTIDE ANTIBIOTIC |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
ES2283425T3 (en) * | 2000-08-03 | 2007-11-01 | Antares Pharma Ipl Ag | NEW COMPOSITION FOR THE TRANSDERMAL AND / OR TRANSMUCTIVE ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURE ADEQUATE THERAPEUTIC LEVELS. |
PE20020300A1 (en) * | 2000-08-22 | 2002-05-10 | Pharmacia Corp | COMPOSITION OF SOLUTION OF AN ANTIBIOTIC DRUG BASED ON OXAZOLIDINONE WITH IMPROVEMENT OF DRUG LOAD |
PE20020578A1 (en) | 2000-10-10 | 2002-08-14 | Upjohn Co | A TOPICAL ANTIBIOTIC COMPOSITION FOR THE TREATMENT OF EYE INFECTIONS |
US6566556B2 (en) * | 2000-12-19 | 2003-05-20 | Nippon Shokubai Co., Ltd. | Method for production of alkanolamine and apparatus therefor |
JP2005503446A (en) * | 2001-01-11 | 2005-02-03 | イーストマン ケミカル カンパニー | Cyclodextrin sulfonate, guest inclusion complex, production method thereof and related substances |
US20020146409A1 (en) * | 2001-01-30 | 2002-10-10 | Herring Steven W. | Methods for stabilizing lyophilized blood proteins |
IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
US6579898B2 (en) | 2001-03-01 | 2003-06-17 | Pfizer Inc. | Compositions having improved bioavailability |
US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
AP2003002900A0 (en) * | 2001-05-01 | 2003-12-31 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
AU2002331527A1 (en) * | 2001-07-20 | 2003-02-24 | Dynamit Nobel Gmbh | Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases |
US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
DE60322665D1 (en) | 2002-02-01 | 2008-09-18 | Pfizer Prod Inc | PHARMACEUTICAL PHARMACEUTICAL FORM WITH CONTROLLED RELEASE OF A CHOLESTERYL SAMPLE TRANSFER PROTEIN INHIBITOR |
EP1478404A1 (en) * | 2002-02-22 | 2004-11-24 | Pharmacia Corporation | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
BR0307893A (en) * | 2002-02-22 | 2004-12-07 | Pharmacia Corp | Ophthalmic formulation with gum system |
US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
GB0212749D0 (en) * | 2002-06-01 | 2002-07-10 | Boots Co Plc | Personal care compositions |
BR0313602A (en) * | 2002-08-20 | 2005-06-21 | Bristol Myers Squibb Co | Aripiprazole Complex Method and Formulation |
AU2003275329B2 (en) * | 2002-09-13 | 2008-04-03 | Cydex Pharmaceuticals, Inc. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
US20040058895A1 (en) * | 2002-09-18 | 2004-03-25 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | Transdermal delivery system for water insoluble drugs |
IL152573A (en) * | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | Transdermal delivery system for anti-emetic medication |
ES2606464T3 (en) * | 2003-01-14 | 2017-03-24 | Yeda Research And Development Co. | Parenteral peptide formulations for the treatment of systemic lupus erythematosus |
CA2513331A1 (en) * | 2003-01-14 | 2004-08-05 | Teva Pharmaceutical Industries Ltd | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
AU2004229291A1 (en) * | 2003-04-18 | 2004-10-28 | Advanced Medicine Research Institute | Remedies for diseases to be applied to eye |
US7157446B2 (en) * | 2003-05-02 | 2007-01-02 | Bristol Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
US6960300B2 (en) * | 2003-09-08 | 2005-11-01 | Sami Labs Limited | Process for preparing water soluble diterpenes and their applications |
MXPA06003316A (en) | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues. |
US7129042B2 (en) * | 2003-11-03 | 2006-10-31 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting severe acute respiratory syndrome coronavirus |
KR20070005586A (en) * | 2003-12-31 | 2007-01-10 | 사이덱스 인크 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
US20050234018A1 (en) * | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
JP5616569B2 (en) | 2004-04-15 | 2014-10-29 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
US20050250738A1 (en) * | 2004-05-06 | 2005-11-10 | Mosher Gerold L | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
ES2510840T3 (en) * | 2004-05-10 | 2014-10-21 | Onyx Therapeutics, Inc. | Compounds for enzymatic proteasome inhibition |
ITMI20041763A1 (en) * | 2004-09-16 | 2004-12-16 | Altergon Sa | NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE |
US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
US20060105045A1 (en) * | 2004-11-08 | 2006-05-18 | Buchanan Charles M | Cyclodextrin solubilizers for liquid and semi-solid formulations |
WO2006052922A2 (en) * | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds |
DK1819353T3 (en) * | 2004-12-07 | 2011-05-16 | Proteolix Inc | Composition for proteasome inhibition |
EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
JP2008536865A (en) * | 2005-04-15 | 2008-09-11 | アルバート・アインシユタイン・カレツジ・オブ・メデイシン・オブ・イエシバ・ユニバーシテイ | Vitamin K for prevention and treatment of rash secondary to anti-EGFR therapy |
EP1874292A2 (en) * | 2005-04-24 | 2008-01-09 | Wyeth | Methods for modulating bladder function |
ES2393768T3 (en) | 2005-05-26 | 2012-12-27 | Neuron Systems, Inc | Quinoline derivative for the treatment of retinal diseases |
US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
WO2006134877A1 (en) * | 2005-06-13 | 2006-12-21 | Takeda Pharmaceutical Company Limited | Injection |
US20080146643A1 (en) * | 2005-06-15 | 2008-06-19 | Pfizer Limited | Combination |
US20080176865A1 (en) * | 2005-06-15 | 2008-07-24 | Pfizer Limited | Substituted arylpyrazoles |
US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
DE102005041860A1 (en) * | 2005-09-02 | 2007-03-08 | Schering Ag | Nano-particle embedded- and charged-complex, useful for the production of a pharmaceutical composition, comprises two complex partners, where the complex partner is an embedded anionic and a cationic active substance |
US20100204178A1 (en) * | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
AU2006299501B2 (en) | 2005-09-30 | 2012-11-29 | Lundbeck Llc | Novel parenteral carbamazepine formulation |
JP5465432B2 (en) | 2005-10-26 | 2014-04-09 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | Sulfoalkyl ether cyclodextrin composition and process for producing the same |
HUE034863T2 (en) | 2005-11-09 | 2018-03-28 | Onyx Therapeutics Inc | Compound for enzyme inhibition |
JP5334588B2 (en) | 2005-11-28 | 2013-11-06 | マリナス ファーマシューティカルズ | Ganaxolone preparation, method for producing the same, and use thereof |
US20070135586A1 (en) * | 2005-12-09 | 2007-06-14 | Shreyas Chakravarti | Polyamide blend compositions formed article and process thereof |
BRPI0620225A2 (en) * | 2005-12-20 | 2011-11-01 | Tika Läkemedel Ab | methods and systems for the distribution of corticosteroids having an increased pharmacokinetic profile |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
CA2642577A1 (en) * | 2006-02-15 | 2007-08-23 | Tika Lakemedel Ab | Methods of manufacturing corticosteroid solutions |
CA2644656A1 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Treatment of pain |
CL2007000773A1 (en) * | 2006-03-24 | 2008-01-25 | Wyeth Corp | Use of compounds derived from condensed diazepine for the treatment of a cognitive disorder such as add or adhd; or its use to treat spm or pmdd. |
WO2007112065A2 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Methods for treating cognitive and other disorders |
AR060087A1 (en) * | 2006-03-24 | 2008-05-21 | Wyeth Corp | NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF DEPRESSION |
CL2007000774A1 (en) * | 2006-03-24 | 2008-03-07 | Wyeth Corp | USE OF COMPOUNDS DERIVED FROM CONDENSED DIAZEPIN TO TREAT URINARY INCONTINENCE. |
US20070238789A1 (en) * | 2006-03-31 | 2007-10-11 | Chin-Ming Chang | Prednisolone acetate compositions |
KR20090037388A (en) * | 2006-04-18 | 2009-04-15 | 이케이알 테라퓨틱스, 인코포레이티드 | Pre-mixed, ready-to-use iv bolus compositions and methods of use |
NZ571460A (en) | 2006-04-21 | 2010-10-29 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
CN100374468C (en) * | 2006-05-25 | 2008-03-12 | 重庆通量精细化工有限公司 | Synthetic process for water soluble sulfoalkyl ether-beta-cyclic dextrine |
NZ603303A (en) | 2006-06-19 | 2014-05-30 | Onyx Therapeutics Inc | Peptide epoxyketones for proteasome inhibition |
US9428582B2 (en) * | 2006-07-03 | 2016-08-30 | Genmab A/S | Method of treating rash in patients undergoing anti-EGFR therapy |
AR061889A1 (en) | 2006-07-13 | 2008-10-01 | Medichem Sa | IMPROVED PROCESS FOR THE PREPARATION OF VORICONAZOL |
US20100022481A1 (en) * | 2006-08-02 | 2010-01-28 | Dong Wang | Drug Carriers, Their Synthesis, and Methods of Use Thereof |
US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
EP2061458B1 (en) * | 2006-09-15 | 2014-12-10 | Regents of the University of Minnesota | Topiramate compositions and methods for their use |
US8455471B2 (en) | 2006-10-20 | 2013-06-04 | Icos Corporation | Compositions of CHK1 inhibitors and cyclodextrin |
US8158609B1 (en) * | 2006-11-02 | 2012-04-17 | Novartis Ag | Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen |
KR100822133B1 (en) * | 2006-11-06 | 2008-04-15 | 한미약품 주식회사 | Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate |
EP2094308B1 (en) * | 2006-11-21 | 2011-01-12 | Novartis AG | Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
AU2008222592B2 (en) * | 2007-03-02 | 2013-09-26 | Detsamma Investments Pty Ltd | Compositions and methods for delivery of anti-cancer agents |
AU2015255164B2 (en) * | 2007-04-27 | 2017-06-08 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
US20100216823A1 (en) * | 2007-05-24 | 2010-08-26 | Pfizer Inc. | Spirocyclic Derivatives |
ES2493641T3 (en) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Nasal administration of aqueous corticosteroid solutions |
TWI428132B (en) | 2007-07-02 | 2014-03-01 | Lilly Co Eli | Potentiation of cancer chemotherapy |
KR100929920B1 (en) | 2007-09-05 | 2009-12-04 | 주식회사 마크로케어 | Method for preparing clathrate containing hydrophobic physiologically active ingredient in cyclodextrin and derivatives thereof and use of clathrate prepared thereby |
CL2008002777A1 (en) * | 2007-09-21 | 2010-01-22 | Wyeth Corp | Method of preparing chiral diazepinoquinoline compounds by recrystallization in a ternary solvent system. |
WO2009045497A1 (en) | 2007-10-04 | 2009-04-09 | Proteolix, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
EP2057982A1 (en) * | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
US8040246B2 (en) * | 2007-12-04 | 2011-10-18 | Avaya Inc. | Systems and methods for facilitating a first response mission at an incident scene |
US8192721B2 (en) * | 2007-12-13 | 2012-06-05 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing toxicity associated with gadolinium-based contrast agents |
US8815953B2 (en) * | 2008-03-13 | 2014-08-26 | Spectrum Pharmaceuticals, Inc. | Formulations of vitamin K analogs for topical use |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
WO2009137611A2 (en) * | 2008-05-06 | 2009-11-12 | Board Of Regents, The University Of Texas System | Treatment of pulmonary fungal infection with voriconazole via inhalation |
US20110144202A1 (en) * | 2008-06-16 | 2011-06-16 | Uwe Marx | Concentrated oxaliplatin solution and its method of preparation |
WO2010014617A1 (en) * | 2008-07-28 | 2010-02-04 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
US20100093872A1 (en) * | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
EA035100B1 (en) | 2008-10-21 | 2020-04-28 | Оникс Терапьютикс, Инк. | Combination therapy with peptide epoxyketones |
KR101767689B1 (en) | 2008-11-15 | 2017-08-11 | 멜린타 테라퓨틱스, 인크. | Antimicrobiral compositions |
TWI504598B (en) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | Crystalline tripeptide epoxy ketone protease inhibitors |
BRPI1012301A2 (en) | 2009-05-29 | 2015-09-22 | Cydex Pharmaceuticals Inc | injectable melphalan compositions comprising a cyclodextrin derivative and methods of preparing and using the same |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
US8492538B1 (en) | 2009-06-04 | 2013-07-23 | Jose R. Matos | Cyclodextrin derivative salts |
HUE048542T2 (en) | 2009-06-16 | 2020-08-28 | Pfizer | Dosage forms of apixaban |
DE102009034368A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases |
WO2011041593A1 (en) * | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
SI2525798T1 (en) | 2010-01-21 | 2018-01-31 | Drawbridge Pharmaceuticals Pty Ltd. | Anaesthetic formulation |
CA2791651C (en) | 2010-03-01 | 2019-08-20 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
CN106036793B (en) * | 2010-03-13 | 2020-11-06 | 伊斯顿庞德实验室有限公司 | Fat-binding compositions |
AU2011245630B2 (en) | 2010-04-07 | 2014-07-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
BR112012030014B1 (en) | 2010-05-26 | 2021-07-13 | Neurophyxia B.V. | SOLUBLE AQUEOUS FORMULATIONS OF 2-IMINOBIOTIN |
US20120142768A1 (en) * | 2010-06-11 | 2012-06-07 | Baxter Healthcare S.A. | Formulations including amiodarone and salts thereof and methods of their manufacture and use |
WO2012061413A2 (en) | 2010-11-01 | 2012-05-10 | Marshall Edwards, Inc. | Isoflavonoid compositions and methods for the treatment of cancer |
DK2667877T3 (en) | 2011-01-26 | 2018-06-14 | Allergan Inc | ANDROGEN COMPOSITION FOR TREATMENT OF Ophthalmic condition |
TWI544922B (en) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | High concentration olopatadine ophthalmic composition |
HUE062616T2 (en) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
MX346432B (en) | 2011-09-18 | 2017-03-21 | Euro-Celtique S A * | Pharmaceutical compositions. |
US20150291654A1 (en) | 2011-10-14 | 2015-10-15 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
TW201332572A (en) | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | Pharmaceutical preparation comprising substituted β -cyclodextrin |
TWI573792B (en) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | Novel therapeutic agents |
TW201336527A (en) | 2012-02-10 | 2013-09-16 | Alcon Res Ltd | Aqueous pharmaceutical composition with enhanced stability |
DK2814849T3 (en) | 2012-02-15 | 2020-03-09 | Cydex Pharmaceuticals Inc | Process for Preparation of Cyclodextrin Derivatives |
RU2747757C2 (en) | 2012-02-28 | 2021-05-13 | Сидекс Фармасьютикалс, Инк. | Compositions of alkylated cyclodextrin and methods of their preparation and application |
JP6081572B2 (en) | 2012-03-30 | 2017-02-15 | ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH | Anthocyanidin complex |
UY34897A (en) | 2012-07-09 | 2014-01-31 | Onyx Therapeutics Inc | PROFESSIONALS OF PEPTIDIC INHIBITORS OF EXPOXI CETONA PROTEASA |
JP2015524444A (en) | 2012-08-03 | 2015-08-24 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Cyclodextrins for the treatment of lysosomal storage diseases |
JP2015534970A (en) * | 2012-10-17 | 2015-12-07 | ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH | Anthocyanidin conjugates for the treatment of multiple myeloma |
UA121095C2 (en) | 2012-10-22 | 2020-04-10 | Сідекс Фармасьютікалс, Інк. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
WO2014075935A1 (en) * | 2012-11-15 | 2014-05-22 | Sapiotec Gmbh | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient |
WO2014090583A1 (en) * | 2012-12-11 | 2014-06-19 | Sapiotec Gmbh | Delphinidin for combating melanoma cells |
CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
TR201817995T4 (en) | 2013-03-13 | 2019-02-21 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS AND METHODS OF USE |
CA2905346A1 (en) | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
PT3498725T (en) | 2013-04-17 | 2021-09-09 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy |
PL2986624T3 (en) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
CN105555277B (en) | 2013-07-19 | 2022-01-11 | 萨奇治疗股份有限公司 | Neuroactive steroid compounds, compositions and uses thereof |
US20160229887A1 (en) | 2013-08-23 | 2016-08-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
RU2572334C2 (en) * | 2013-12-06 | 2016-01-10 | Общество С Ограниченной Ответственностью "Луфатен" | Clathrate complex of arabinogalactan or arabic gum with 20-hydroxyecdysones, method for producing it (versions), pharmaceutical composition and medicinal product |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
PL3149018T3 (en) | 2014-05-29 | 2021-01-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
JP6628745B2 (en) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス, インコーポレイテッド | Oxysterols and methods of using same |
US9987267B2 (en) | 2014-06-18 | 2018-06-05 | Elanco Us Inc. | Transdermal formulations of pergolide and uses thereof |
US10851184B2 (en) | 2014-08-22 | 2020-12-01 | Cydex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
JOP20200195A1 (en) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
CN112121171A (en) | 2014-10-07 | 2020-12-25 | 萨奇治疗股份有限公司 | Neuroactive compounds and methods of use thereof |
PL3206493T3 (en) | 2014-10-16 | 2021-01-25 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
NZ731034A (en) | 2014-10-16 | 2024-02-23 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
ES2793237T3 (en) | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Compositions and methods for treating CNS disorders |
CA2974123C (en) | 2015-02-02 | 2023-08-01 | Mei Pharma, Inc. | Combination of benzopyran derivative and glycolytic inhibitors for cancer therapy |
CN115487313A (en) | 2015-02-06 | 2022-12-20 | 马瑞纳斯制药公司 | Intravenous ganaxolone formulations and uses thereof |
DK3258939T3 (en) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF |
JP6971963B2 (en) | 2015-03-19 | 2021-11-24 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | Compositions containing silymarin and sulfoalkyl ether cyclodextrins and methods of using them |
WO2016164763A1 (en) | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
EA033892B1 (en) | 2015-06-10 | 2019-12-05 | Втесс, Инк. | Hydroxypropyl beta-cyclodextrin compositions and methods |
CN113292623A (en) | 2015-07-06 | 2021-08-24 | 萨奇治疗股份有限公司 | Pregnansterol and methods of use thereof |
RU2021100377A (en) | 2015-07-06 | 2021-05-18 | Сейдж Терапьютикс, Инк. | OXYSTEROLES AND METHODS OF THEIR APPLICATION |
EP4316591A3 (en) | 2015-07-06 | 2024-04-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
WO2017007805A1 (en) | 2015-07-09 | 2017-01-12 | Gilead Sciences, Inc. | Intravenous formulations of a late sodium current inhibitor |
EP3337486B1 (en) | 2015-08-21 | 2024-04-03 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
KR20180111948A (en) | 2016-02-18 | 2018-10-11 | 멜린타 테라퓨틱스, 인크. | Oritavansin preparation |
BR112018069533A2 (en) | 2016-02-28 | 2019-04-16 | Aldeyra Therapeutics, Inc. | treatment of cyclodextrin eye allergic conditions |
HUE059491T2 (en) | 2016-04-01 | 2022-11-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
MX2018013472A (en) | 2016-05-09 | 2019-02-28 | Aldeyra Therapeutics Inc | Combination treatment of ocular inflammatory disorders and diseases. |
US20190030170A1 (en) * | 2016-05-10 | 2019-01-31 | Vireo Health LLC | Cannabinoid formulations with improved solubility |
JP6966486B2 (en) | 2016-07-07 | 2021-11-17 | セージ セラピューティクス, インコーポレイテッド | Oxysterols and how to use them |
IL264129B1 (en) | 2016-07-11 | 2024-01-01 | Sage Therapeutics Inc | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
CA3030420A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
EP3481387A4 (en) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | Methods and compositions for treatment of epileptic disorders |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
CN115850361A (en) | 2016-09-30 | 2023-03-28 | 萨奇治疗股份有限公司 | C7 substituted oxysterol and methods of using same as NMDA modulators |
WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
DK3529257T3 (en) | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | OXYSTEROLS AND METHODS OF USING THEREOF |
JP2019532079A (en) | 2016-10-18 | 2019-11-07 | セージ セラピューティクス, インコーポレイテッド | Oxysterols and methods of use |
CN110022857A (en) | 2016-11-18 | 2019-07-16 | 艾库里斯抗感染治疗有限公司 | Based on the amidine of modified cyclodextrin and acidulant replace 'beta '-lactam compounds novel formulation, its preparation and as antimicrobial pharmceutical compositions purposes |
US10875853B2 (en) | 2017-01-20 | 2020-12-29 | Shenzhen Targetrx, Inc. | (Hetero)arylamide compound for inhibiting protein kinase activity |
CN110343092B (en) | 2017-01-20 | 2021-03-02 | 深圳市塔吉瑞生物医药有限公司 | (hetero) aryl amides for inhibiting protein kinase activity |
US11274164B2 (en) | 2017-02-07 | 2022-03-15 | Biophore India Pharmaceuticals Pvt. Ltd. | Method for the preparation of sulfobutylether beta cyclodextrin sodium |
CN110431130A (en) | 2017-03-16 | 2019-11-08 | 奥尔德拉医疗公司 | Multi-crystalline compounds and its purposes |
ES2928147T3 (en) | 2017-04-01 | 2022-11-15 | Shengke Pharmaceuticals Jiangsu Ltd | 1H-imidazo[4,5-H]quinazoline compound as protein kinase inhibitor |
BR112019023074A2 (en) | 2017-05-03 | 2020-06-09 | Cydex Pharmaceuticals Inc | composition containing cyclodextrin and busulfan |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
EP3626241A4 (en) | 2017-06-26 | 2020-05-27 | Shenzhen Targetrx, Inc. | N-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof |
EP3626709A1 (en) | 2017-06-26 | 2020-03-25 | Shenzhen Targetrx, Inc. | Indazole compound for use in inhibiting kinase activity, composition and application thereof |
WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
EP3666774B1 (en) | 2017-08-11 | 2022-05-11 | Shengke Pharmaceuticals (Jiangsu) Ltd. | 1h-pyrazolo[4,3-h]quinazoline compound serving as protein kinase inhibitor |
US11267810B2 (en) | 2017-08-30 | 2022-03-08 | Shenzhen Targetrx, Inc. | Aminopyrimidine compound and composition comprising same and use thereof |
CN110997637B (en) | 2017-09-05 | 2022-09-27 | 保仕健生物科技(上海)有限公司 | Aromatic derivative, preparation method and application thereof in medicine |
EP3694500A4 (en) | 2017-10-10 | 2021-06-30 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
WO2019075362A1 (en) | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
CN109369721A (en) | 2017-12-21 | 2019-02-22 | 深圳市塔吉瑞生物医药有限公司 | For inhibiting the aryl phosphorous oxides of kinase activity |
EP3715343B1 (en) | 2017-12-21 | 2024-02-14 | Shenzhen TargetRx, Inc. | Diphenylaminopyrimidine compound for inhibiting kinase activity |
JP7076159B2 (en) | 2017-12-21 | 2022-05-27 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | New antiviral nucleoside reverse transcriptase inhibitor |
JP7076158B2 (en) | 2017-12-21 | 2022-05-27 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | New antiviral nucleoside reverse transcriptase inhibitor |
EP3728285A1 (en) | 2017-12-22 | 2020-10-28 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
EP3728284A1 (en) | 2017-12-22 | 2020-10-28 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
US11718642B2 (en) | 2018-01-12 | 2023-08-08 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
JP7092405B2 (en) | 2018-04-16 | 2022-06-28 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | Di (hetero) aryl macrocycle to inhibit kinase activity |
EP3782998B1 (en) | 2018-04-16 | 2023-05-10 | Shenzhen TargetRx, Inc. | Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof |
EP3801481A1 (en) | 2018-05-30 | 2021-04-14 | Convert Pharmaceuticals SA | Prodrugs and medical uses thereof |
WO2019232201A1 (en) | 2018-06-01 | 2019-12-05 | Bayer Cropscience Lp | Stabilized fungicidal composition comprising cyclodextrin |
EP3795571A4 (en) | 2018-07-02 | 2021-04-28 | Shenzhen TargetRx, Inc. | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity |
WO2020011141A1 (en) | 2018-07-12 | 2020-01-16 | 深圳市塔吉瑞生物医药有限公司 | Diarylpyrazole compound, composition comprising same, and use thereof |
WO2020015615A1 (en) | 2018-07-17 | 2020-01-23 | 深圳市塔吉瑞生物医药有限公司 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity |
CN112714762A (en) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | Polymorphic compounds and uses thereof |
WO2020068986A1 (en) | 2018-09-25 | 2020-04-02 | Aldeyra Therapeutics, Inc. | Formulations for treatment of dry eye disease |
US20210386737A1 (en) | 2018-10-10 | 2021-12-16 | Shenzhen Targetrx, Inc. | Dihydroimidazopyrazinone compound, composition including same, and use thereof |
BR112021009428A2 (en) | 2018-10-12 | 2021-08-31 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS REPLACED AT POSITION 10 BY A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS |
AR116771A1 (en) | 2018-10-19 | 2021-06-09 | Sage Therapeutics Inc | ACTIVE NEUROSTEROIDS AND THEIR METHODS OF USE |
JP2022510683A (en) | 2018-12-05 | 2022-01-27 | セージ セラピューティクス, インコーポレイテッド | Neurostimulatory steroids and how to use them |
EP3878852A4 (en) | 2018-12-06 | 2021-12-15 | Shenzhen TargetRx, Inc. | Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
BR112021012242A2 (en) | 2018-12-21 | 2021-09-28 | Sage Therapeutics, Inc. | 3-ALPHA-HYDROXY-17-BETA-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF |
WO2020125391A1 (en) | 2018-12-21 | 2020-06-25 | 深圳市塔吉瑞生物医药有限公司 | Aminopyrimidine compound used for inhibiting activity of protein kinase |
CN113271923A (en) | 2019-01-04 | 2021-08-17 | Sq创新股份公司 | Furosemide pharmaceutical composition and application thereof |
EP3911331A4 (en) | 2019-01-14 | 2023-01-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | Tetrazolone substituted steroids and use thereof |
WO2020168963A1 (en) | 2019-02-18 | 2020-08-27 | 深圳市塔吉瑞生物医药有限公司 | Substituted fused aromatic ring derivative, composition and use thereof |
US11802113B2 (en) | 2019-02-27 | 2023-10-31 | Shenzhen Targetrx, Inc. | Substituted pyrazole compounds, compositions containing same, and use thereof |
JP2022526917A (en) | 2019-03-26 | 2022-05-27 | アルデイラ セラピューティクス, インコーポレイテッド | Ophthalmic preparations and their use |
CN113993585A (en) | 2019-03-27 | 2022-01-28 | 英矽智能科技知识产权有限公司 | Bicyclic JAK inhibitors and uses thereof |
MA56046A (en) | 2019-05-31 | 2022-04-06 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS AND ASSOCIATED COMPOSITIONS |
US20220378799A1 (en) | 2019-06-06 | 2022-12-01 | Beijing Tide Pharmaceutical Co., Ltd. | 2, 4, 6-tri-substituted pyrimidine compound as atr kinase inhibitor |
TW202114695A (en) | 2019-06-27 | 2021-04-16 | 美商賽吉醫療公司 | Compositions and methods for treating cns disorders |
WO2020264509A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
WO2020264495A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
JP2022543837A (en) | 2019-08-05 | 2022-10-14 | マリナス ファーマシューティカルズ, インコーポレイテッド | Ganaxolone for use in treating status epilepticus |
CN114555127A (en) | 2019-08-06 | 2022-05-27 | L.E.A.F.控股集团公司 | Method for preparing polyglutamated antifolates and use of compositions thereof |
US20220306659A1 (en) | 2019-08-23 | 2022-09-29 | Beijing Tide Pharmaceutical Co., Ltd. | Compound inhibiting and inducing degradation of egfr and alk |
WO2021057877A1 (en) | 2019-09-26 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | Substituted aromatic fused ring derivative and composition comprising same, and use thereof |
EP4056570A4 (en) | 2019-11-01 | 2023-12-20 | ShanghaiTech University | Eed inhibitor, and preparation method therefor and use thereof |
CA3158280A1 (en) | 2019-12-06 | 2021-06-10 | Alex Aimetti | Ganaxolone for use in treating tuberous sclerosis complex |
JP2023506086A (en) | 2019-12-16 | 2023-02-14 | 北京泰徳製薬股▲フン▼有限公司 | Compounds that inhibit EGFR kinase and induce its degradation |
JP2023512617A (en) | 2020-01-17 | 2023-03-28 | 晟科薬業(江蘇)有限公司 | Novel compounds as PCSK9 inhibitors |
CA3175324A1 (en) | 2020-03-18 | 2021-09-23 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
EP4155307A4 (en) | 2020-05-20 | 2023-09-13 | Beijing Tide Pharmaceutical Co., Ltd. | 2,4,6-tri-substituted pyrimidine compounds as atr kinase inhibitors |
WO2021262836A1 (en) | 2020-06-24 | 2021-12-30 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
CA3185963A1 (en) | 2020-07-13 | 2022-01-20 | Cheung Ling Cheng | Pyrazolopyrimidine compound used as atr kinase inhibitor |
KR20230057380A (en) | 2020-08-27 | 2023-04-28 | 셍커 파마슈티컬스 (지앙수) 엘티디. | 1H-imidazo[4,5-H]quinazoline compounds as novel selective FLT3 inhibitors |
WO2022115381A1 (en) | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions and methods for treating cns disorders cross reference to related application |
AU2022319712A1 (en) | 2021-07-28 | 2024-01-18 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
WO2023049295A1 (en) | 2021-09-22 | 2023-03-30 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
WO2023144692A1 (en) * | 2022-01-25 | 2023-08-03 | Leiutis Pharmaceuticals Llp | Novel naproxen sodium preparations for parenteral |
US11958917B2 (en) | 2022-02-18 | 2024-04-16 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
WO2023205165A1 (en) * | 2022-04-22 | 2023-10-26 | Brii Biosciences Offshore Limited | A polymyxin composition and methods for producing the same |
EP4332087A1 (en) | 2022-04-29 | 2024-03-06 | Beijing Jitai Pharmaceutical Technology Co., Ltd. | Lipid nanoparticles |
CN116969851A (en) | 2022-04-29 | 2023-10-31 | 北京剂泰医药科技有限公司 | Ionizable lipid compounds |
WO2024026337A1 (en) | 2022-07-27 | 2024-02-01 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3426011A (en) * | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3816393A (en) * | 1970-06-10 | 1974-06-11 | Ono Pharmaceutical Co | Clathrate compounds of prostaglandins or their analogues with cyclo-dextrin |
US4497803A (en) * | 1982-04-12 | 1985-02-05 | Takeda Chemical Industries, Ltd. | Inclusion compound of lankacidin-group antibiotic and use thereof |
US4535152A (en) * | 1983-02-14 | 1985-08-13 | Chinoin, Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Water soluble cyclodextrin polymers substituted by ionic groups and process for the preparation thereof |
US4555504A (en) * | 1981-01-23 | 1985-11-26 | Burroughs Wellcome Co. | Inclusion complex of β-cyclodextrin and digoxin |
US4582900A (en) * | 1983-12-17 | 1986-04-15 | Hoechst Aktiengesellschaft | Water-soluble mixed ethers of β-cyclodextrin and a process for their preparation |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4638058A (en) * | 1983-12-17 | 1987-01-20 | Hoechst Aktiengesellschaft | Ethers of beta-cyclodextrin and a process for their preparation |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4746734A (en) * | 1985-02-28 | 1988-05-24 | Sanraku Incorporated | Partially methylated cyclodextrins and process for producing the same |
US4764604A (en) * | 1985-03-15 | 1988-08-16 | Janssen Pharmaceutica N.V. | Derivatives of gamma-cyclodextrin |
US4774329A (en) * | 1987-08-04 | 1988-09-27 | American Maize-Products Company | Controlled release agent for cetylpyridinium chloride |
US4808232A (en) * | 1986-12-08 | 1989-02-28 | American Maize-Products Company | Separation and purification of cyclodextrins |
US4869904A (en) * | 1986-12-26 | 1989-09-26 | Nisshin Flour Milling Co., Ltd. | Sustained release drug preparation |
US5134127A (en) * | 1990-01-23 | 1992-07-28 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991013100A1 (en) * | 1990-03-02 | 1991-09-05 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
-
1992
- 1992-07-27 US US07/918,702 patent/US5376645A/en not_active Expired - Lifetime
-
1993
- 1993-07-26 KR KR1019940700951A patent/KR100279111B1/en not_active IP Right Cessation
- 1993-07-26 TJ TJ96000377A patent/TJ275B/en unknown
- 1993-07-26 JP JP50467894A patent/JP3393253B2/en not_active Expired - Fee Related
- 1993-07-26 MD MD96-0306A patent/MD1813C2/en not_active IP Right Cessation
- 1993-07-26 GE GEAP19932498A patent/GEP19991649B/en unknown
- 1993-07-26 PT PT93918302T patent/PT620828E/en unknown
- 1993-07-26 WO PCT/US1993/006880 patent/WO1994002518A1/en active IP Right Grant
- 1993-07-26 CA CA002119154A patent/CA2119154C/en not_active Expired - Lifetime
- 1993-07-26 AT AT93918302T patent/ATE217325T1/en active
- 1993-07-26 AU AU47799/93A patent/AU672814B2/en not_active Ceased
- 1993-07-26 RU RU94028890A patent/RU2113442C1/en not_active IP Right Cessation
- 1993-07-26 DE DE69331900T patent/DE69331900T3/en not_active Expired - Lifetime
- 1993-07-26 DK DK93918302T patent/DK0620828T4/en active
- 1993-07-26 ES ES93918302T patent/ES2176206T5/en not_active Expired - Lifetime
- 1993-07-26 EP EP93918302A patent/EP0620828B2/en not_active Expired - Lifetime
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3426011A (en) * | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3816393A (en) * | 1970-06-10 | 1974-06-11 | Ono Pharmaceutical Co | Clathrate compounds of prostaglandins or their analogues with cyclo-dextrin |
US4555504A (en) * | 1981-01-23 | 1985-11-26 | Burroughs Wellcome Co. | Inclusion complex of β-cyclodextrin and digoxin |
US4497803A (en) * | 1982-04-12 | 1985-02-05 | Takeda Chemical Industries, Ltd. | Inclusion compound of lankacidin-group antibiotic and use thereof |
US4535152A (en) * | 1983-02-14 | 1985-08-13 | Chinoin, Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Water soluble cyclodextrin polymers substituted by ionic groups and process for the preparation thereof |
US4638058A (en) * | 1983-12-17 | 1987-01-20 | Hoechst Aktiengesellschaft | Ethers of beta-cyclodextrin and a process for their preparation |
US4582900A (en) * | 1983-12-17 | 1986-04-15 | Hoechst Aktiengesellschaft | Water-soluble mixed ethers of β-cyclodextrin and a process for their preparation |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4746734A (en) * | 1985-02-28 | 1988-05-24 | Sanraku Incorporated | Partially methylated cyclodextrins and process for producing the same |
US4764604A (en) * | 1985-03-15 | 1988-08-16 | Janssen Pharmaceutica N.V. | Derivatives of gamma-cyclodextrin |
US4764604B1 (en) * | 1985-03-15 | 1990-06-12 | Janssen Pharmaceutica Nv | |
US4808232A (en) * | 1986-12-08 | 1989-02-28 | American Maize-Products Company | Separation and purification of cyclodextrins |
US4869904A (en) * | 1986-12-26 | 1989-09-26 | Nisshin Flour Milling Co., Ltd. | Sustained release drug preparation |
US4774329A (en) * | 1987-08-04 | 1988-09-27 | American Maize-Products Company | Controlled release agent for cetylpyridinium chloride |
US5134127A (en) * | 1990-01-23 | 1992-07-28 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
Cited By (450)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0709099A3 (en) * | 1994-09-28 | 1996-07-24 | Senju Pharma Co | An aqueous nasal suspension comprising cyclodextrin |
WO1996041646A2 (en) * | 1995-06-13 | 1996-12-27 | Dyer, Alison, Margaret | Pharmaceutical compositions containing lornoxicam and cyclodextrin |
WO1996041646A3 (en) * | 1995-06-13 | 1997-02-13 | Dyer Alison Margaret | Pharmaceutical compositions containing lornoxicam and cyclodextrin |
US6232304B1 (en) | 1996-05-07 | 2001-05-15 | Pfizer Inc. | Inclusion complexes of aryl-heterocyclic salts |
US6399777B2 (en) | 1996-05-07 | 2002-06-04 | Pfizer Inc. | Inclusion complexes of aryl-heterocyclic salts |
WO1998047518A1 (en) * | 1997-04-17 | 1998-10-29 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Use of cholesterol-lowering agents to influence signal transduction processes in the cell membrane and in the prophylaxis or treatment of prion-associated diseases or alzheimer's disease |
WO1998050077A1 (en) * | 1997-05-05 | 1998-11-12 | Cydex Inc. | Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent |
AU729671B2 (en) * | 1997-05-05 | 2001-02-08 | Cydex Pharmaceuticals, Inc. | Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent |
WO1998056422A1 (en) * | 1997-06-13 | 1998-12-17 | The University Of Kansas | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
US6133248A (en) * | 1997-06-13 | 2000-10-17 | Cydex, Inc. | Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof |
AP912A (en) * | 1997-06-21 | 2001-12-08 | Pfizer | Pharmaceutical-formulations containing voriconazole. |
US6632803B1 (en) | 1997-06-21 | 2003-10-14 | Pfizer Inc | Pharmaceutical formulations containing voriconazole |
AU724799B2 (en) * | 1997-06-21 | 2000-09-28 | Pfizer Inc. | Pharmaceutical formulations containing voriconazole |
WO1998058677A1 (en) * | 1997-06-21 | 1998-12-30 | Pfizer Limited | Pharmaceutical formulations containing voriconazole |
EP0889056A3 (en) * | 1997-07-01 | 1999-04-07 | Pfizer Products Inc. | Process for making a cyclodextrin |
EP0889056A2 (en) * | 1997-07-01 | 1999-01-07 | Pfizer Products Inc. | Process for making a cyclodextrin |
US6153746A (en) * | 1997-07-01 | 2000-11-28 | Pfizer Inc. | Process for making a cyclodextrin |
WO1999042111A1 (en) * | 1998-02-23 | 1999-08-26 | Cyclops, Ehf. | High-energy cyclodextrin complexes |
US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
FR2784584A1 (en) * | 1998-10-14 | 2000-04-21 | Adir | Preparation of nasal sprays useful for treating menopausal disorders, comprises dissolving a cyclodextrin compound in water and adding a sex hormone |
WO2000021503A1 (en) * | 1998-10-14 | 2000-04-20 | Adir Et Compagnie | Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin |
US7375096B1 (en) | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
WO2000033885A1 (en) * | 1998-12-04 | 2000-06-15 | California Institute Of Technology | Supramolecular complexes containing therapeutic agents |
EP1897559A1 (en) * | 1999-01-13 | 2008-03-12 | Cydex Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
WO2000041704A1 (en) * | 1999-01-13 | 2000-07-20 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
EP1859790A2 (en) * | 1999-01-13 | 2007-11-28 | Cydex Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
AU758376B2 (en) * | 1999-01-13 | 2003-03-20 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
EP1859790A3 (en) * | 1999-01-13 | 2008-03-05 | Cydex Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
EP1897560A1 (en) * | 1999-01-13 | 2008-03-12 | Cydex Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
US6900309B1 (en) | 1999-06-15 | 2005-05-31 | Pfizer Inc | Purine derivatives |
WO2001000243A1 (en) * | 1999-06-29 | 2001-01-04 | Pfizer Limited | Pharmaceutical complex |
US6713461B1 (en) | 1999-06-29 | 2004-03-30 | Pfizer Inc. | Pharmaceutical complex |
US6962923B2 (en) | 1999-07-29 | 2005-11-08 | Pfizer Inc. | Pyrazole compositions |
US6448236B1 (en) | 1999-10-14 | 2002-09-10 | Pfizer Inc | Purine derivatives |
US6350735B1 (en) | 1999-10-14 | 2002-02-26 | Pfizer Inc | Purine derivatives |
WO2001030391A3 (en) * | 1999-10-27 | 2001-12-20 | Farmarc Nederland Bv | Pharmaceutical composition containing midazolam |
WO2001030391A2 (en) * | 1999-10-27 | 2001-05-03 | Farmarc Nederland Bv | Pharmaceutical composition containing midazolam |
WO2001072338A1 (en) * | 2000-03-28 | 2001-10-04 | Farmarc Nederland Bv | Alprazolam inclusion complexes and pharmaceutical compositions thereof |
US7368460B2 (en) | 2000-05-26 | 2008-05-06 | Pfizer, Inc. | Tropane derivatives useful in therapy |
US7576097B2 (en) | 2000-05-26 | 2009-08-18 | Pfizer, Inc. | Tropane derivatives useful in therapy |
EP1990341A1 (en) | 2000-05-26 | 2008-11-12 | Pfizer Inc. | Triazolyl tropane derivatives as CCR5 modulators |
US7094769B2 (en) | 2000-06-06 | 2006-08-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
US6753322B2 (en) | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
US7238676B2 (en) | 2000-06-27 | 2007-07-03 | Pfizer Inc. | Purine derivatives |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
US6420557B1 (en) | 2000-07-28 | 2002-07-16 | Pfizer Inc. | Crystalline therapeutic agent |
US6624158B2 (en) | 2000-09-15 | 2003-09-23 | Pfizer Inc | Purine derivatives |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
US8063044B2 (en) | 2001-04-10 | 2011-11-22 | Pfizer Inc. | Pyrazole derivatives |
US7109228B2 (en) | 2001-04-10 | 2006-09-19 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
WO2003002153A1 (en) * | 2001-06-28 | 2003-01-09 | Wyeth | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins |
WO2003002152A2 (en) * | 2001-06-29 | 2003-01-09 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
WO2003002152A3 (en) * | 2001-06-29 | 2003-05-01 | Maxygen Aps | Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
EP2341146A2 (en) | 2001-07-05 | 2011-07-06 | Imperial College Innovations Limited | Method for determining chromatin structure |
US6653339B2 (en) | 2001-08-15 | 2003-11-25 | Pfizer Inc. | Method of treating irritable bowel syndrome |
US7022727B2 (en) | 2001-12-06 | 2006-04-04 | Pfizer Inc | Crystalline drug form |
US6852746B2 (en) | 2001-12-06 | 2005-02-08 | Pfizer Inc | Crystalline drug form |
US7348317B2 (en) | 2001-12-24 | 2008-03-25 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
US7060717B2 (en) | 2002-02-11 | 2006-06-13 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
US6949573B2 (en) | 2002-02-11 | 2005-09-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
US6756392B2 (en) | 2002-02-11 | 2004-06-29 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
WO2003080599A1 (en) | 2002-03-26 | 2003-10-02 | Novartis International Pharmaceutical Ltd. | Stable hydrate of a muscarinic receptor antagonist |
EP2336124A1 (en) | 2002-03-26 | 2011-06-22 | Novartis International Pharmaceutical Ltd. | Stable hydrate of a muscarinic receptor antagonist |
US7217721B2 (en) | 2002-04-08 | 2007-05-15 | Pfizer, Inc. | Tropane derivatives useful in therapy |
US7579471B2 (en) | 2002-04-08 | 2009-08-25 | Pfizer, Inc. | Tropane derivatives useful in therapy |
US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
US8058344B2 (en) | 2002-04-19 | 2011-11-15 | Imperial Innovations Ltd | Glycodendrimers having biological activity |
WO2003099288A1 (en) * | 2002-05-28 | 2003-12-04 | Taisho Pharmaceutical Co., Ltd. | Medicinal composition |
US6818662B2 (en) | 2002-05-28 | 2004-11-16 | Taisho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
US6914160B1 (en) | 2002-08-28 | 2005-07-05 | Pfizer Inc | Oxytocin inhibitors |
US8389499B2 (en) | 2002-09-06 | 2013-03-05 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8404662B2 (en) | 2002-09-06 | 2013-03-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US9550860B2 (en) | 2002-09-06 | 2017-01-24 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8252276B2 (en) | 2002-09-06 | 2012-08-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8314230B2 (en) | 2002-09-06 | 2012-11-20 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580242B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580244B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8680202B2 (en) | 2002-09-06 | 2014-03-25 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8603454B2 (en) | 2002-09-06 | 2013-12-10 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8399431B2 (en) | 2002-09-06 | 2013-03-19 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8609081B2 (en) | 2002-09-06 | 2013-12-17 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580243B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8518388B2 (en) | 2002-09-06 | 2013-08-27 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8475781B2 (en) | 2002-09-06 | 2013-07-02 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
WO2004024765A1 (en) | 2002-09-12 | 2004-03-25 | University Of Bath | Crystal structure of an angiotensin-converting enzyme (ace) and uses thereof |
US7704319B2 (en) | 2002-09-12 | 2010-04-27 | University Of Bath | Crystal structure of an angiotensin-converting enzyme (ACE) and uses thereof |
US7901507B2 (en) | 2002-09-12 | 2011-03-08 | University Of Bath | Crystal structure of an angiotensin-converting enzyme (ACE) and uses thereof |
US8594947B2 (en) | 2002-09-12 | 2013-11-26 | University Of Bath | Crystal structure of an angiotensin-converting enzyme (ACE) and uses thereof |
US7230025B2 (en) | 2002-09-26 | 2007-06-12 | Pfizer, Inc. | Pyrazole derivatives |
US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
US7902188B2 (en) | 2002-12-10 | 2011-03-08 | Pfizer Inc. | Morpholine dopamine agonists |
US7576081B2 (en) | 2002-12-10 | 2009-08-18 | Pfizer Inc. | Morpholine dopamine agonists |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
US7432299B2 (en) | 2002-12-13 | 2008-10-07 | Pfizer Inc. | Method of treatment for sexual dysfunction |
EP2196201A2 (en) | 2002-12-13 | 2010-06-16 | Warner-Lambert Company LLC | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms |
US7183294B2 (en) | 2003-03-14 | 2007-02-27 | Pfizer Inc. | Indole derivatives useful for the treatment of diseases |
EP2277513A2 (en) | 2003-04-25 | 2011-01-26 | Pfizer Inc. | Treatment of incontinence with 5htc2 agonists |
US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
US7776885B2 (en) | 2003-09-03 | 2010-08-17 | Pfizer, Inc. | Benzimidazolone compounds having 5-HT4 receptor agonistic activity |
EP2181995A2 (en) | 2003-09-03 | 2010-05-05 | Glaxo Group Limited | Salts and crystalline form of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-sufanyl)-acetate |
US7220772B2 (en) | 2003-09-05 | 2007-05-22 | Pfizer, Inc. | Pyrazole derivatives |
EP2156863A2 (en) | 2003-09-12 | 2010-02-24 | Pfizer Limited | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
US7790740B2 (en) | 2003-10-03 | 2010-09-07 | Pfizer Inc | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation |
US7309790B2 (en) | 2003-10-03 | 2007-12-18 | Pfizer Inc | Chemical compounds |
EP2301628A1 (en) | 2003-10-15 | 2011-03-30 | Zalicus Inc. | Methods and reagents for the treatment of immunoinflammatory disorders |
EP2070550A1 (en) | 2003-10-15 | 2009-06-17 | Combinatorx, Incorporated | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases |
WO2005051293A2 (en) | 2003-11-21 | 2005-06-09 | Combinatorx, Incorporated | Methods and reagents for the treatment of inflammatory disorders |
US10799599B2 (en) | 2003-12-31 | 2020-10-13 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US10207008B2 (en) | 2003-12-31 | 2019-02-19 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US10159752B2 (en) | 2003-12-31 | 2018-12-25 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US9827324B2 (en) | 2003-12-31 | 2017-11-28 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US7528170B2 (en) | 2004-01-22 | 2009-05-05 | Pfizer Inc. | Sulfonamide derivatives for the treatment of diseases |
US7244766B2 (en) | 2004-01-22 | 2007-07-17 | Pfizer Inc | Sulfonamide derivatives for the treatment of diseases |
US8013019B2 (en) | 2004-01-22 | 2011-09-06 | Pfizer Inc | Sulfonamide derivatives for the treatment of diseases |
US7767715B2 (en) | 2004-01-22 | 2010-08-03 | Pfizer Inc | Sulfonamide derivatives for the treatment of diseases |
US7351742B2 (en) | 2004-01-22 | 2008-04-01 | Pfizer Inc. | Sulfonamide derivatives for the treatment of diseases |
US7629358B2 (en) | 2004-03-17 | 2009-12-08 | Pfizer Inc | Compounds useful for the treatment of diseases |
US7687533B2 (en) | 2004-03-18 | 2010-03-30 | Pfizer Inc. | N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides |
US7538141B2 (en) | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
US7241810B2 (en) | 2004-03-23 | 2007-07-10 | Pfizer Inc | Formamide derivatives for the treatment of diseases |
US7547731B2 (en) | 2004-03-23 | 2009-06-16 | Pfizer Inc | Formamide derivatives for the treatment of diseases |
US11464862B2 (en) | 2004-04-23 | 2022-10-11 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
US10117940B2 (en) | 2004-04-23 | 2018-11-06 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
US10668160B2 (en) | 2004-04-23 | 2020-06-02 | Cydex Pharmaceuticals, Inc. | DPI formulation containing sulfoalkyl ether cyclodextrin |
US7659394B2 (en) | 2004-04-30 | 2010-02-09 | Pfizer Inc | Substituted morpholine compounds for the treatment of central nervous system disorders |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
US7557121B2 (en) | 2004-05-12 | 2009-07-07 | Pfizer Inc | Tetrahydronaphthyridine derivatives |
US7705020B2 (en) | 2004-06-15 | 2010-04-27 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
US7595329B2 (en) | 2004-06-15 | 2009-09-29 | Pfizer Inc | Benzimidazolone carboxylic acid derivatives |
US8076356B2 (en) | 2004-08-12 | 2011-12-13 | Pfizer Inc. | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors |
US7511057B2 (en) | 2004-08-12 | 2009-03-31 | Pfizer Inc. | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors |
US7858643B2 (en) | 2004-08-26 | 2010-12-28 | Agouron Pharmaceuticals, Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
US8785632B2 (en) | 2004-08-26 | 2014-07-22 | Agouron Pharmaceuticals, Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
US7598393B2 (en) | 2004-11-02 | 2009-10-06 | Pfizer Inc. | Sulfonyl benzimidazole derivatives |
US7781427B2 (en) | 2004-11-05 | 2010-08-24 | Wyeth Llc | Process for preparing quinoline compounds and products obtained therefrom |
US8703099B2 (en) | 2005-02-24 | 2014-04-22 | Dr Pharma Nova, Llc | Registry method and control system for DEA schedule II-V medicines |
WO2006097817A1 (en) | 2005-03-17 | 2006-09-21 | Pfizer Japan Inc. | N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain |
US7618972B2 (en) | 2005-03-21 | 2009-11-17 | Pfizer Inc | Substituted triazole derivatives as oxytocin antagonists |
US8076293B2 (en) | 2005-04-19 | 2011-12-13 | Gabriel Stavros Panayi | Use of BiP or a variant, homologue, derivative or fragment thereof in the manufacture of a medicament for the prevention or treatment of bone loss or bone resorption |
US7642350B2 (en) | 2005-05-04 | 2010-01-05 | Pfizer Limited | Purine derivatives |
US7968584B2 (en) | 2005-06-15 | 2011-06-28 | Pfizer Inc. | Substituted arylpyrazoles |
US7538134B2 (en) | 2005-06-15 | 2009-05-26 | Pfizer Inc. | Substituted arylpyrazoles |
US7645786B2 (en) | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
US7671196B2 (en) | 2005-07-26 | 2010-03-02 | Wyeth Llc | Diazepinoquinolines, synthesis thereof, and intermediates thereto |
US8846901B2 (en) | 2005-10-26 | 2014-09-30 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US10202468B2 (en) | 2005-10-26 | 2019-02-12 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US10703826B2 (en) | 2005-10-26 | 2020-07-07 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US9617352B2 (en) | 2005-10-26 | 2017-04-11 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
WO2007072163A2 (en) | 2005-12-20 | 2007-06-28 | Pfizer Limited | Pyrimidine derivatives |
EP2017259A2 (en) | 2005-12-21 | 2009-01-21 | Pfizer Products Inc. | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein |
US9670473B2 (en) | 2006-01-10 | 2017-06-06 | Angiodesign (Uk) Limited | Crystals of angiotensin-converting enzyme (ACE) |
US8796006B2 (en) | 2006-01-10 | 2014-08-05 | University Of Bath | Crystal structure of the N-terminal domain of angiotensin converting enzyme and uses thereof |
US9434933B2 (en) | 2006-01-10 | 2016-09-06 | Angiodesign (Uk) Ltd. | Crystal |
USRE45003E1 (en) | 2006-01-17 | 2014-07-08 | Novacta Biosystems Limited | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae |
US8465947B2 (en) | 2006-01-17 | 2013-06-18 | Novacta Biosystems Limited | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. liguriae |
US7989416B2 (en) | 2006-01-17 | 2011-08-02 | Novacta Biosystems Limited | Lantibiotic biosynthetic gene clusters from A. garbadinensis and A. Liguriae |
US8790910B2 (en) | 2006-07-25 | 2014-07-29 | The Secretary Of State For Defence | Live vaccine strain |
US8323664B2 (en) | 2006-07-25 | 2012-12-04 | The Secretary Of State For Defence | Live vaccine strains of Francisella |
WO2008024914A2 (en) | 2006-08-23 | 2008-02-28 | Intellect Neurosciences Inc. | 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom |
EP2380566A2 (en) | 2006-09-15 | 2011-10-26 | Stevia APS | Treatment of insulin resistance or diseases associated with insulin resistance using steviol or isosteviol |
US8466166B2 (en) | 2006-09-21 | 2013-06-18 | Raqualia Pharma Inc. | Benzimidazole derivatives as selective acid pump inhibitors |
US7744890B2 (en) | 2006-10-12 | 2010-06-29 | Wyeth Llc | Methods and compositions with reduced opalescence |
US8044052B2 (en) | 2006-10-18 | 2011-10-25 | Pfizer Inc. | Biaryl ether urea compounds |
WO2008050199A2 (en) | 2006-10-23 | 2008-05-02 | Pfizer Japan Inc. | Substituted phenylmethyl bicyclocarboxyamide compounds |
EP2395077A1 (en) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
US8192951B2 (en) | 2006-11-03 | 2012-06-05 | Wyeth Llc | Glycolysis-inhibiting substances in cell culture |
US9610360B2 (en) | 2007-01-24 | 2017-04-04 | Ceruliean Pharma Inc. | Polymer drug conjugates with tether groups for controlled drug delivery |
US8497365B2 (en) | 2007-01-24 | 2013-07-30 | Mark E. Davis | Cyclodextrin-based polymers for therapeutics delivery |
EP2924113A1 (en) | 2007-03-02 | 2015-09-30 | Wyeth LLC | Use of copper and glutamate in cell culture for production of polypeptides |
US9012180B2 (en) | 2007-03-02 | 2015-04-21 | Wyeth Llc | Use of copper and glutamate in cell culture for production of polypeptides |
US10512697B2 (en) | 2007-04-27 | 2019-12-24 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US9125945B2 (en) | 2007-04-27 | 2015-09-08 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US8853236B2 (en) | 2007-04-27 | 2014-10-07 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US9623045B2 (en) | 2007-04-27 | 2017-04-18 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
US10034947B2 (en) | 2007-04-27 | 2018-07-31 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
WO2008147556A2 (en) | 2007-05-25 | 2008-12-04 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
US8575094B2 (en) | 2007-07-18 | 2013-11-05 | Novacta Biosystems Limited | Use of type-B lantibiotic-based compounds having antimicrobial activity |
US8329644B2 (en) | 2007-07-18 | 2012-12-11 | Novacta Biosystems Limited | Lantibiotic-based compounds having antimicrobial activity |
US8486935B2 (en) | 2007-09-05 | 2013-07-16 | Rigel Pharmaceuticals, Inc. | Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine |
US8653049B2 (en) | 2008-03-17 | 2014-02-18 | Imuthes Limited | Normuramyl glycopeptide compounds |
US8518952B2 (en) | 2008-08-06 | 2013-08-27 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors |
EP2163253A1 (en) | 2008-09-15 | 2010-03-17 | Charité-Universitätsmedizin Berlin | Extracts from the plant hornstedtia scyphifera and immnunosuppressive effects thereof |
US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
WO2010058858A1 (en) | 2008-11-21 | 2010-05-27 | ラクオリア創薬株式会社 | Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity |
WO2010080528A1 (en) | 2008-12-17 | 2010-07-15 | Genentech, Inc. | Hepatitis c virus combination therapy |
WO2010079443A1 (en) | 2009-01-12 | 2010-07-15 | Pfizer Limited | Sulfonamide derivatives |
US8283371B2 (en) | 2009-01-14 | 2012-10-09 | Novacta Biosystems Limited | Compounds |
US8741945B2 (en) | 2009-01-14 | 2014-06-03 | Novacta Biosystems Limited | Compounds |
WO2010082019A1 (en) | 2009-01-14 | 2010-07-22 | Novacta Biosystems Limited | Actagardine derivatives, and pharmaceutical use thereof |
WO2010082018A1 (en) | 2009-01-14 | 2010-07-22 | Novacta Biosystems Limited | Deoxyactagardine derivatives |
WO2010089544A1 (en) | 2009-02-04 | 2010-08-12 | Novacta Biosystems Limited | Actagardine derivatives |
US8729031B2 (en) | 2009-02-04 | 2014-05-20 | Novacta Biosystems Limited | Compounds |
WO2010103070A2 (en) | 2009-03-12 | 2010-09-16 | Charité - Universitätsmedizin Berlin | Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity |
EP2233502A1 (en) | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
WO2010109010A1 (en) | 2009-03-27 | 2010-09-30 | Deutsches Rheuma-Forschungszentrum Berlin (Drfz) | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
US8609108B2 (en) | 2009-04-14 | 2013-12-17 | The Secretary Of State For Defence | Gamma-glutamyl transpeptidase attenuated Francisella |
US9399067B2 (en) | 2009-05-13 | 2016-07-26 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
US8835407B2 (en) | 2009-05-13 | 2014-09-16 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
US10111863B2 (en) | 2009-05-13 | 2018-10-30 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
WO2010136940A1 (en) | 2009-05-29 | 2010-12-02 | Pfizer Limited | Novel glucocorticoid receptor agonists |
EP2266563A1 (en) | 2009-06-11 | 2010-12-29 | Charité-Universitätsmedizin Berlin (Charité) | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
WO2011077313A1 (en) | 2009-12-22 | 2011-06-30 | Pfizer Inc. | Piperidinecarboxamides as mpges - 1 inhibitors |
EP3489236A1 (en) | 2009-12-23 | 2019-05-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of fused heteroaromatic pyrrolidinones |
EP2902392A1 (en) | 2009-12-23 | 2015-08-05 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
WO2011079051A1 (en) | 2009-12-23 | 2011-06-30 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
EP3825316A1 (en) | 2009-12-23 | 2021-05-26 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
WO2011083387A1 (en) | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
WO2011095768A1 (en) | 2010-02-02 | 2011-08-11 | Novacta Biosystems Limited | Lantibiotic salts |
WO2011095769A1 (en) | 2010-02-02 | 2011-08-11 | Novacta Biosystems Limited | Actagardine derivatives, and pharmaceutical use thereof |
US9006392B2 (en) | 2010-02-02 | 2015-04-14 | Novacta Biosystems Limited | Actagardine derivatives, and pharmaceutical use thereof |
WO2011104649A1 (en) | 2010-02-25 | 2011-09-01 | Pfizer Limited | Peptide analogues |
WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
WO2011154871A1 (en) | 2010-06-10 | 2011-12-15 | Pfizer Limited | Hepatitis c virus inhibitors |
WO2012004706A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
WO2012004714A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
WO2012007877A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012007883A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
WO2012007868A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012007861A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
WO2012007869A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012020221A1 (en) | 2010-08-11 | 2012-02-16 | Novacta Biosystems Limited | Compounds |
WO2012020219A2 (en) | 2010-08-11 | 2012-02-16 | Novacta Biosystems Limited | Formulations for infusion of type b lantibiotics |
WO2012020222A1 (en) | 2010-08-11 | 2012-02-16 | Novacta Biosystems Limited | Compounds |
US9192569B2 (en) | 2010-08-11 | 2015-11-24 | Novacta Biosystems Limited | Formulations for infusion of type B lantibiotics |
WO2012020220A1 (en) | 2010-08-11 | 2012-02-16 | Novacta Biosystems Limited | Compounds |
WO2012025745A1 (en) | 2010-08-24 | 2012-03-01 | Imperial Innovations Limited | Glycodendrimers of polypropyletherimine |
WO2012025744A1 (en) | 2010-08-24 | 2012-03-01 | Imperial Innovations Limited | Glycodendrimers of polypropyletherimine |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
WO2012066442A1 (en) | 2010-11-15 | 2012-05-24 | Pfizer Limited | Inhibitors of hiv replication |
WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
WO2012148548A1 (en) | 2011-02-25 | 2012-11-01 | Takeda Pharmaceutical Company Limited | N-substituted oxazinopteridines and oxazinopteridinones |
WO2012120398A1 (en) | 2011-03-04 | 2012-09-13 | Pfizer Limited | Aryl substituted carboxamide derivatives as trpm8 modulators |
WO2012137089A1 (en) | 2011-04-05 | 2012-10-11 | Pfizer Limited | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
US9187463B2 (en) | 2011-05-18 | 2015-11-17 | Raqualia Pharma Inc. | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid |
WO2012157288A1 (en) | 2011-05-18 | 2012-11-22 | Raqualia Pharma Inc. | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid |
KR20210104170A (en) | 2011-05-18 | 2021-08-24 | 라퀄리아 파마 인코포레이티드 | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid |
WO2012171561A1 (en) | 2011-06-15 | 2012-12-20 | Synthon Bv | Stabilized voriconazole composition |
WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
US8957025B2 (en) | 2011-07-13 | 2015-02-17 | Pfizer Inc. | Enkephalin analogues |
WO2013008123A1 (en) | 2011-07-13 | 2013-01-17 | Pfizer Limited | Enkephalin analogues |
US8895544B2 (en) | 2011-07-27 | 2014-11-25 | Pfizer Limited | Indazoles |
WO2013014567A1 (en) | 2011-07-27 | 2013-01-31 | Pfizer Limited | Indazoles |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
WO2013017989A1 (en) | 2011-08-02 | 2013-02-07 | Pfizer Inc. | Crizotinib for use in the treatment of cancer |
WO2013017136A1 (en) | 2011-08-02 | 2013-02-07 | Pensieve Biosciences Cyprus Limited | Treatment of cognitive impairment |
WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
WO2013057722A1 (en) | 2011-10-21 | 2013-04-25 | Pfizer Limited | New salt and medical use |
WO2013061205A2 (en) | 2011-10-26 | 2013-05-02 | Pfizer Limited | Chemical compounds |
EP3243815A1 (en) | 2011-10-28 | 2017-11-15 | Inhibitaxin Limited | Pyridazine derivatives useful in therapy |
WO2013061297A1 (en) | 2011-10-28 | 2013-05-02 | Pfizer Limited | Pyridazine Derivatives Useful in Therapy |
WO2013088315A1 (en) | 2011-12-15 | 2013-06-20 | Pfizer Limited | Sulfonamide derivatives |
WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
WO2013102826A1 (en) | 2012-01-04 | 2013-07-11 | Pfizer Limited | N-aminosulfonyl benzamides |
US9718879B2 (en) | 2012-01-26 | 2017-08-01 | Imperial Innovations Ltd. | Methods of treating pain by inhibition of VGF activity |
WO2013110945A1 (en) | 2012-01-26 | 2013-08-01 | Imperial Innovations Ltd | Methods of treating pain by inhibition of vgf activity |
US8927587B2 (en) | 2012-02-03 | 2015-01-06 | Pfizer Limited | Chemical compounds |
WO2013114250A1 (en) | 2012-02-03 | 2013-08-08 | Pfizer Inc. | Benziimidazole and imidazopyridine derivatives as sodium channel modulators |
WO2013132376A1 (en) | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
WO2014011568A1 (en) | 2012-07-10 | 2014-01-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives which act as pi3k inhibitors |
WO2014039831A1 (en) | 2012-09-07 | 2014-03-13 | Takeda Pharmaceutical Company Limited | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES |
US9533989B2 (en) | 2012-09-18 | 2017-01-03 | Ziarco Pharma Ltd. | Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors |
US10065964B2 (en) | 2012-09-18 | 2018-09-04 | Ziarco Pharma Ltd. | Pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors |
WO2014049488A1 (en) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
WO2014053968A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
WO2014053967A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors |
WO2014053965A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Tropomyosin-related kinase inhibitors |
US8822494B2 (en) | 2012-11-08 | 2014-09-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9133190B2 (en) | 2012-11-08 | 2015-09-15 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9527843B2 (en) | 2012-11-08 | 2016-12-27 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
EP3323821A1 (en) | 2012-11-08 | 2018-05-23 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2014072881A1 (en) | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US9617275B2 (en) | 2012-11-08 | 2017-04-11 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
WO2014072882A1 (en) | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds as dopamine d1 ligands |
US10179779B2 (en) | 2012-11-21 | 2019-01-15 | Raqualia Pharma Inc. | Polymorph forms |
KR20150085515A (en) | 2012-11-21 | 2015-07-23 | 라퀄리아 파마 인코포레이티드 | Polymorph forms |
US9328104B2 (en) | 2012-12-03 | 2016-05-03 | Pfizer Inc. | Selective androgen receptor modulators |
WO2014087298A1 (en) | 2012-12-03 | 2014-06-12 | Pfizer Inc. | Novel selective androgen receptor modulators |
WO2014091368A1 (en) | 2012-12-14 | 2014-06-19 | Pfizer Limited | Imidazopyridazine derivatives as gabaa receptor modulators |
EP3339303A1 (en) | 2012-12-21 | 2018-06-27 | Pfizer Inc | Aryl and heteroaryl fused lactams |
WO2014097041A1 (en) | 2012-12-21 | 2014-06-26 | Pfizer Inc. | Aryl and heteroaryl fused lactams |
WO2014128588A1 (en) | 2013-02-21 | 2014-08-28 | Pfizer Inc. | Solid forms of a selective cdk4/6 inhibitor |
EP3431475A1 (en) | 2013-02-21 | 2019-01-23 | Pfizer Inc | Solid forms of a selective cdk4/6 inhibitor |
WO2014164558A1 (en) | 2013-03-11 | 2014-10-09 | Takeda Pharmaceutical Company Limited | Pyridinyl and fused pyridinyl triazolone derivatives |
EP3235814A1 (en) | 2013-03-11 | 2017-10-25 | Takeda Pharmaceutical Company Limited | Pyridinyl and fused pyridinyl triazolone derivatives |
EP2784083A1 (en) | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
WO2014170793A1 (en) | 2013-04-19 | 2014-10-23 | Pfizer Limited | Sulfonamides for the treatment of gout |
WO2014170792A1 (en) | 2013-04-19 | 2014-10-23 | Pfizer Limited | Sulfonamide derivatives as urat-1 inhibitors |
WO2014181213A1 (en) | 2013-05-10 | 2014-11-13 | Pfizer Inc. | Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide |
US9139561B2 (en) | 2013-06-27 | 2015-09-22 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US11014909B2 (en) | 2013-06-27 | 2021-05-25 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US11964961B2 (en) | 2013-06-27 | 2024-04-23 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US10696658B2 (en) | 2013-06-27 | 2020-06-30 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9527831B2 (en) | 2013-06-27 | 2016-12-27 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9822097B2 (en) | 2013-06-27 | 2017-11-21 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
WO2014207601A1 (en) | 2013-06-27 | 2014-12-31 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US10421744B2 (en) | 2013-06-27 | 2019-09-24 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US10093655B2 (en) | 2013-06-27 | 2018-10-09 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9107923B2 (en) | 2013-06-27 | 2015-08-18 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
EP3421462A1 (en) | 2013-06-27 | 2019-01-02 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
US9364458B2 (en) | 2013-07-08 | 2016-06-14 | Abbvie Inc. | Stabilized pharmaceutical dosage forms comprising atrasentan |
US10016393B2 (en) | 2013-07-08 | 2018-07-10 | Abbvie Inc. | Stabilized pharmaceutical dosage forms comprising atrasentan |
EP3239148A1 (en) | 2013-09-12 | 2017-11-01 | AbbVie Inc. | Atrasentan mandelate salts for the treatment of kidney diseases |
US9637476B2 (en) | 2013-09-12 | 2017-05-02 | Abbvie Inc. | Atrasentan mandelate salts |
WO2015038571A1 (en) | 2013-09-12 | 2015-03-19 | Abbvie, Inc. | Atrasentan mandelate salts for the treatement of kidney diseases |
US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
WO2015050989A2 (en) | 2013-10-01 | 2015-04-09 | Cs Therapeutics Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
WO2015092610A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2015106012A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
WO2015106014A1 (en) | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
CN104971355A (en) * | 2014-04-02 | 2015-10-14 | 上海现代药物制剂工程研究中心有限公司 | Rivaroxaban-containing composition and preparation method thereof |
CN104971355B (en) * | 2014-04-02 | 2018-04-24 | 上海现代药物制剂工程研究中心有限公司 | Composition containing razaxaban and preparation method thereof |
WO2015159175A1 (en) | 2014-04-15 | 2015-10-22 | Pfizer Inc. | Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety |
US9688698B2 (en) | 2014-04-25 | 2017-06-27 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
WO2015162515A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US9868744B2 (en) | 2014-04-25 | 2018-01-16 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9850232B2 (en) | 2014-04-25 | 2017-12-26 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
WO2015162518A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US10077272B2 (en) | 2014-04-25 | 2018-09-18 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9540352B2 (en) | 2014-04-25 | 2017-01-10 | Pfizer Inc. | Substituted 1,7-naphthyridines as dopamine D1 ligands |
WO2015162516A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
US9745317B2 (en) | 2014-04-28 | 2017-08-29 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine D1 ligands |
WO2015166366A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
WO2015170218A1 (en) | 2014-05-07 | 2015-11-12 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
US9518052B2 (en) | 2014-05-14 | 2016-12-13 | Pfizer Inc. | Pyrazolopyridines and pyrazolopyrimidines |
WO2015173683A1 (en) | 2014-05-14 | 2015-11-19 | Pfizer Inc. | Pyrazolopyridines and pyrazolopyrimidines |
US10022376B2 (en) | 2014-05-14 | 2018-07-17 | Pfizer Inc. | Pyrazolopyridines and pyrazolopyrimidines |
WO2015173684A1 (en) | 2014-05-15 | 2015-11-19 | Pfizer Inc. | Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile |
US9920043B2 (en) | 2014-05-15 | 2018-03-20 | Pfizer Inc. | Crystalline form of 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]iosoquinoline-1-carbonitrile |
US9988370B2 (en) | 2014-05-20 | 2018-06-05 | Raqualia Pharma Inc. | Benzisoxazole derivative salt |
WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
US10328082B2 (en) | 2014-05-30 | 2019-06-25 | Pfizer Inc. | Methods of use and combinations |
WO2015181797A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Benzenesulfonamides useful as sodium channel inhibitors |
WO2015189744A1 (en) | 2014-06-12 | 2015-12-17 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
EP3521285A1 (en) | 2014-06-17 | 2019-08-07 | Pfizer Inc | Substituted dihydroisoquinolinone compounds |
WO2015193768A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
WO2015193765A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Substituted dihydroisoquinolinone compounds |
WO2016009296A1 (en) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2016009303A1 (en) | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors |
WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
WO2016034971A1 (en) | 2014-09-04 | 2016-03-10 | Pfizer Limited | Sulfonamides derivatives as urat1 inhibitors |
WO2016044433A2 (en) | 2014-09-16 | 2016-03-24 | Biopharma Works | Metformin derivatives |
US11518765B2 (en) | 2014-09-29 | 2022-12-06 | The Provost, The Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
US11229652B2 (en) | 2014-09-29 | 2022-01-25 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Treatments for autoimmune disease |
US10793572B2 (en) | 2014-09-29 | 2020-10-06 | The Provost Fellows Foundation Scholars And The Other Members Of Board Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
WO2016067143A1 (en) | 2014-10-28 | 2016-05-06 | Pfizer Inc. | N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels |
WO2016097918A1 (en) | 2014-12-18 | 2016-06-23 | Pfizer Inc. | Pyrimidine and triazine derivatives and their use as axl inhibitors |
US9593097B2 (en) | 2014-12-18 | 2017-03-14 | Pfizer Inc. | Axl inhibitors |
WO2016100778A1 (en) | 2014-12-19 | 2016-06-23 | Takeda Pharmaceutical Company Limited | Fumagillol derivatives |
WO2016116628A1 (en) | 2015-01-22 | 2016-07-28 | Phytoplant Research S.L. | Methods of purifying cannabinoids, compositions and kits thereof |
EP3556376A1 (en) | 2015-01-22 | 2019-10-23 | Phytoplant Research S.L. | Methods of purifying cannabinoids, compositions and kits thereof |
EP3050574A1 (en) | 2015-01-28 | 2016-08-03 | Universite De Bordeaux | New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease |
EP3613435A1 (en) | 2015-01-28 | 2020-02-26 | Universite De Bordeaux | Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease |
US10428104B2 (en) | 2015-02-24 | 2019-10-01 | Pfizer Inc. | Substituted nucleoside derivatives useful as anticancer agents |
US10624972B2 (en) | 2015-03-13 | 2020-04-21 | Endocyte, Inc. | Conjugates for treating diseases |
WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
US10723711B2 (en) | 2015-07-31 | 2020-07-28 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
US9845301B2 (en) | 2015-07-31 | 2017-12-19 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
US10428034B2 (en) | 2015-07-31 | 2019-10-01 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
WO2017098367A1 (en) | 2015-12-10 | 2017-06-15 | Pfizer Limited | 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain |
WO2017111179A1 (en) | 2015-12-24 | 2017-06-29 | Takeda Pharmaceutical Company Limited | Cocrystal, production method thereof, and medicament containing cocrystal |
WO2017120429A1 (en) | 2016-01-07 | 2017-07-13 | CS Pharmasciences, Inc. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
WO2017119732A1 (en) | 2016-01-08 | 2017-07-13 | Samsung Electronics Co., Ltd. | Electronic device and operating method thereof |
WO2017122116A1 (en) | 2016-01-15 | 2017-07-20 | Pfizer Inc. | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
WO2017156341A1 (en) | 2016-03-09 | 2017-09-14 | Beijing Percans Oncology Co. Ltd. | Tumor cell suspension cultures and related methods |
CN109071496A (en) * | 2016-03-31 | 2018-12-21 | 武田药品有限公司 | Isoquinolyl triazolone compound |
WO2017173111A1 (en) * | 2016-03-31 | 2017-10-05 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
US10220037B2 (en) | 2016-06-06 | 2019-03-05 | Pfizer Inc. | Substituted carbonucleoside derivatives useful as anticancer agents |
US10709709B2 (en) | 2016-06-06 | 2020-07-14 | Pfizer Inc. | Substituted carbonucleoside derivatives useful as anticancer agents |
WO2017212385A1 (en) | 2016-06-06 | 2017-12-14 | Pfizer Inc. | Substituted carbonucleoside derivatives useful as anticancer agents |
WO2018020358A1 (en) | 2016-07-29 | 2018-02-01 | Pfizer Inc. | Cyclic peptides as c5 a receptor antagonists |
WO2018033815A1 (en) | 2016-08-15 | 2018-02-22 | Pfizer Inc. | Pyridopyrimdinone cdk2/4/6 inhibitors |
WO2018096510A1 (en) | 2016-11-28 | 2018-05-31 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
EP4252856A2 (en) | 2016-12-20 | 2023-10-04 | Oligomerix, Inc. | Novel quinazolinones that inhibit the formation of tau oligomers and their method of use |
US10626125B2 (en) | 2017-01-20 | 2020-04-21 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors |
US10329308B2 (en) | 2017-01-20 | 2019-06-25 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors |
WO2018134695A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors |
WO2018134698A1 (en) | 2017-01-23 | 2018-07-26 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
US10858373B2 (en) | 2017-01-23 | 2020-12-08 | Pfizer Inc. | Heterocyclic spiro compounds as MAGL inhibitors |
US11426397B2 (en) | 2017-03-26 | 2022-08-30 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 |
WO2018232202A1 (en) | 2017-06-15 | 2018-12-20 | Takeda Pharmaceutical Company Limited | Tetrahydropyridopyrazine modulators of gpr6 |
US10406157B2 (en) | 2017-06-15 | 2019-09-10 | Takeda Pharmaceutical Company Limited | Tetrahydropyridopyrazine modulators of GPR6 |
US11571423B2 (en) | 2017-06-22 | 2023-02-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
US11773132B2 (en) | 2017-08-30 | 2023-10-03 | Beijing Xuanyi Pharmasciences Co., Ltd. | Cyclic di-nucleotides as stimulator of interferon genes modulators |
WO2019051469A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
US10435389B2 (en) | 2017-09-11 | 2019-10-08 | Krouzon Pharmaccuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 |
WO2019060850A1 (en) | 2017-09-25 | 2019-03-28 | Takeda Pharmaceutical Company Limited | N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivatives useful as hif prolyl hydroxylase inhibitors |
WO2019145552A1 (en) | 2018-01-29 | 2019-08-01 | Phytoplant Research S.L | Methods of purifying cannabinoids using liquid:liquid chromatography |
US10662204B2 (en) | 2018-02-01 | 2020-05-26 | Pfizer Inc. | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents |
WO2019150305A1 (en) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents |
WO2019155399A1 (en) | 2018-02-09 | 2019-08-15 | Pfizer Inc. | Tetrahydroquinazoline derivatives useful as anticancer agents |
US10590115B2 (en) | 2018-02-09 | 2020-03-17 | Pfizer Inc. | Tetrahydroquinazoline derivatives useful as anticancer agents |
WO2019169153A1 (en) | 2018-03-01 | 2019-09-06 | Takeda Pharmaceutical Company Limited | Piperidinyl-3-(aryloxy)propanamides and propanoates |
US10968242B2 (en) | 2018-03-15 | 2021-04-06 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
US10538542B2 (en) | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
WO2019207463A1 (en) | 2018-04-26 | 2019-10-31 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
WO2019243823A1 (en) | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Azaheterocyclic small molecule modulators of human sting |
WO2020016710A1 (en) | 2018-07-19 | 2020-01-23 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
WO2020076728A1 (en) | 2018-10-08 | 2020-04-16 | Takeda Pharmaceutical Company Limited | SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR |
WO2020100027A1 (en) | 2018-11-15 | 2020-05-22 | Pfizer Inc. | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer |
WO2020109994A1 (en) | 2018-11-29 | 2020-06-04 | Pfizer Inc. | Pyrazoles as modulators of hemoglobin |
WO2020152557A1 (en) | 2019-01-23 | 2020-07-30 | Pfizer Inc. | Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative |
WO2020157652A2 (en) | 2019-01-31 | 2020-08-06 | Pfizer Inc. | Cdk2 inhibitors |
WO2020198053A1 (en) | 2019-03-22 | 2020-10-01 | Takeda Pharmaceutical Company Limited | 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases |
WO2020223255A1 (en) | 2019-04-29 | 2020-11-05 | Solent Therapeutics, Llc | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 |
RU2776671C2 (en) * | 2019-07-11 | 2022-07-22 | Общество С Ограниченной Ответственностью "Научно-Исследовательский Центр "Парк Активных Молекул" (Ооо "Ниц Пам") | Use of clathrate complex of 20-hydroxyecdysone with arabinogalactan for normalization of metabolism, increase in non-specific resistance, growth and development of animals |
WO2021009676A1 (en) | 2019-07-17 | 2021-01-21 | Pfizer Inc. | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits |
WO2021014415A2 (en) | 2019-07-25 | 2021-01-28 | Curadev Pharma Pvt. Ltd. | Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2) |
WO2021055326A1 (en) | 2019-09-16 | 2021-03-25 | Takeda Pharmaceutical Company Limited | Azole-fused pyridazin-3(2h)-one derivatives |
WO2021059136A1 (en) | 2019-09-25 | 2021-04-01 | Pfizer Inc. | Polyheterocyclic modulators of sting (stimulator of interferon genes) |
WO2021161230A1 (en) | 2020-02-12 | 2021-08-19 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
WO2021202781A1 (en) | 2020-03-31 | 2021-10-07 | Takeda Pharmaceutical Company Limited | N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as sstr4 agonists |
WO2021202775A1 (en) | 2020-03-31 | 2021-10-07 | Takeda Pharmaceutical Company Limited | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists |
WO2021205363A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors |
WO2021220185A1 (en) | 2020-05-01 | 2021-11-04 | Pfizer Inc. | Azalactam compounds as hpk1 inhibitors |
WO2021225968A1 (en) | 2020-05-04 | 2021-11-11 | Takeda Pharmaceutical Company Limited | Luminally-acting n-(piperidin-4-yl)benzamide derivatives |
WO2021224818A1 (en) | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
WO2022003575A1 (en) | 2020-06-30 | 2022-01-06 | Array Biopharma Inc. | Her2 mutation inhibitors |
WO2022013691A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol |
WO2022013692A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride |
WO2022018667A1 (en) | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
WO2022023438A1 (en) | 2020-07-29 | 2022-02-03 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Compounds |
WO2022023433A1 (en) | 2020-07-29 | 2022-02-03 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Compounds |
WO2022066917A1 (en) | 2020-09-23 | 2022-03-31 | Takeda Pharmaceutical Company Limited | 3-(6-aminopyridin-3-yl)benzamide derivatives as ripk2 inhibitors |
WO2022195462A1 (en) | 2021-03-18 | 2022-09-22 | Pfizer Inc. | Modulators of sting (stimulator of interferon genes) |
US11964978B2 (en) | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
WO2022207673A1 (en) | 2021-03-31 | 2022-10-06 | Sevenless Therapeutics Limited | Sos1 inhibitors and ras inhibitors for use in the treatment of pain |
GB202104609D0 (en) | 2021-03-31 | 2021-05-12 | Sevenless Therapeutics Ltd | New Treatments for Pain |
WO2022214869A2 (en) | 2021-04-07 | 2022-10-13 | Lifearc | Ulk1/2 inhibitors and their use thereof |
WO2022259091A1 (en) | 2021-06-10 | 2022-12-15 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd | Purification of sulfobutylated cyclodextrins with specific ion exchange resins |
US11649299B2 (en) | 2021-06-10 | 2023-05-16 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Purification of sulfobutylated cyclodextrins with specific ion exchange resins |
WO2022269531A1 (en) | 2021-06-26 | 2022-12-29 | Array Biopharma Inc. | Her2 mutation inhibitors |
WO2023017451A1 (en) | 2021-08-11 | 2023-02-16 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
WO2023017452A1 (en) | 2021-08-11 | 2023-02-16 | Curadev Pharma Pvt. Ltd. | Small molecule urea derivatives as sting antagonists |
WO2023099072A1 (en) | 2021-12-01 | 2023-06-08 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Compounds |
WO2023187677A1 (en) | 2022-03-30 | 2023-10-05 | Takeda Pharmaceutical Company Limited | N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives |
WO2023194964A1 (en) | 2022-04-07 | 2023-10-12 | Takeda Pharmaceutical Company Limited | Fused pyridazine derivatives as nlrp3 inhibitors |
WO2024023727A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Novel acc inhibitors |
WO2024033845A1 (en) | 2022-08-10 | 2024-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2024074827A1 (en) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | New treatments for pain |
Also Published As
Publication number | Publication date |
---|---|
US5376645A (en) | 1994-12-27 |
EP0620828A1 (en) | 1994-10-26 |
DE69331900D1 (en) | 2002-06-13 |
TJ275B (en) | 2000-10-05 |
AU672814B2 (en) | 1996-10-17 |
GEP19991649B (en) | 1999-06-14 |
EP0620828B2 (en) | 2008-07-09 |
PT620828E (en) | 2002-10-31 |
AU4779993A (en) | 1994-02-14 |
ES2176206T3 (en) | 2002-12-01 |
CA2119154A1 (en) | 1994-02-03 |
DE69331900T3 (en) | 2009-03-26 |
DK0620828T3 (en) | 2002-08-26 |
RU2113442C1 (en) | 1998-06-20 |
CA2119154C (en) | 1998-06-16 |
KR100279111B1 (en) | 2001-03-02 |
MD1813C2 (en) | 2002-08-31 |
JPH06511513A (en) | 1994-12-22 |
ATE217325T1 (en) | 2002-05-15 |
EP0620828B1 (en) | 2002-05-08 |
ES2176206T5 (en) | 2008-12-01 |
EP0620828A4 (en) | 1996-05-15 |
DK0620828T4 (en) | 2008-11-03 |
DE69331900T2 (en) | 2003-01-16 |
JP3393253B2 (en) | 2003-04-07 |
MD1813B2 (en) | 2001-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0620828B1 (en) | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof | |
US5134127A (en) | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof | |
WO1994002518A9 (en) | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof | |
Szejtli | The properties and potential uses of cyclodextrin derivatives | |
US11208500B2 (en) | Manufacturing process for cyclodextrin derivatives | |
JP4439596B2 (en) | Pharmaceutical composition containing polar drug or polar prodrug having long shelf life, and method for producing the same | |
US7786095B2 (en) | Amphiphilic macrocyclic derivatives and their analogues | |
US5856359A (en) | Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same | |
Rajewski | Development and evaluation of the usefulness and parenteral safety of modified cyclodextrins | |
CN113350526B (en) | Polysaccharide supramolecular polymer drug carrier based on host-guest effect and preparation method thereof | |
Frijlink | Biopharmaceutical aspects of cyclodextrins | |
KUM et al. | THE CYCLODEXTRINS: A REVIEW | |
KR20030068034A (en) | Amphiphilic macrocyclic derivatives and their analogues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR RU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/10-10/10,DRAWINGS,REPLACED BY NEW PAGES 1/10-10/10;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2119154 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019940700951 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993918302 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication |
Free format text: UZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1993918302 Country of ref document: EP |
|
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication |
Free format text: GE |
|
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication |
Free format text: AM,KG,MD,TJ,TM |
|
WWE | Wipo information: entry into national phase |
Ref document number: 96-0306 Country of ref document: MD |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993918302 Country of ref document: EP |